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Neutrophils are recruited in different type of cancer, including lung cancer, where they emerged as 
the most significant negative prognostic factor. Most experimental reports converge toward a pro-
tumorigenic role of neutrophils via direct induction of cancer cell proliferation, promotion of 
metastasis, stimulation of angiogenesis and modulation of T cell responses. Nevertheless, in some 
cancer type and tumor stages, neutrophils exert anti-tumoral properties through direct killing of 
cancer cells and activation of T cell-dependent anti-tumor immunity. Thus, neutrophils in cancer 
display an enormous plasticity and heterogeneity which may be strongly influenced by the tissue 
and the constellation of immune modulating factors. Evaluate the complexity of neutrophils in 
tissue specific tumor microenvironment to unequivocal distinguish immunosuppressive neutrophils 
from other neutrophil subsets represent an important challenge in the field. In addition, 
understanding how these cells accumulate in tissues and how polarize to a pro- or anti-tumorigenic 
phenotype is crucial to develop successful cancer therapies.  
A critical subset of neutrophils expressing high levels of the sialic-acid-binding protein SiglecF (neu-
SiglecFhigh) was identified in KrasG12D/+; Trp53-/- (KP) mouse lung adenocarcinoma that correspond to 
a transcriptionally related human counterpart associated to negative outcomes. Neu-SiglecFhigh are 
mature, long-lived, cells that display tumor promoting functions associated to angiogenesis, matrix 
remodeling and production of ROS. However, the mechanism of recruitment of neu-SiglecFhigh in 
lung cancer and their impact on endogenous anti-tumor T cell responses are still unknown. 
Here, we used a transplantable KP line to investigate the role of the C-X-C motif chemokine 5 (CXCL5) 
in recruitment and accumulation of neu-SiglecFhigh in the microenvironment of lung tumors. By 
genome editing we abrogated the expression of CXCL5 in immunogenic KP cells (KP OVA KOCXCL5) 
and we characterized neutrophils frequencies and T cell activation within lung tumor tissues. We 
observed a drastic decrease of Cxcl5 transcripts followed by a strong reduction of neu-SiglecFhigh in 
KOCXCL5 tumors proving that the chemokine is a key player for their accumulation. Moreover, 
phenotypic and functional analysis of endogenous anti-cancer responses revealed a significant 
expansion of highly activated and cytotoxic tumor specific CD8+ T cells in tumor lacking neu-
SiglecFhigh. Immunofluorescence analysis of lung tissues shown tight CD8 T cell-neutrophils 
interactions, suggesting a contact-mediated mechanism of inhibition. Moreover, administration of 
antibodies to PD-L1 during challenge proved that neu-SiglecFhigh, due to a high expression of PD-L1, 
hamper the full activity of checkpoint blockade. Thus, we infer that targeting the CXCL5-axis could 
be a viable improvement to existing immunotherapy. 
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1. Introduction 
Cancer is one of the leading causes of death worldwide and the most common and aggressive is 
lung cancer. The emergence of lung cancer epidemic in the 20th century has been caused by 
cigarette smoking, the main risk factor for lung cancer development. Other factors include exposure 
to toxic substances (alcohol, air pollution), but also unhealthy diet, lack of physical activity and 
mutation of susceptibility genes. Screenings for patients with high risk for lung cancer showed 
reduction in mortality. In fact, timely detection of lung cancer could delay its progression and after 
the initial diagnosis, accurate staging is critical for determining appropriate therapy and achieve a 
good long-term survival. However, this finding is not echoed in practice. A majority of lung cancer 
cases are diagnosed in symptomatic individuals (e.g., cough, fatigue, chest pain, haemoptysis) that 
reduce the change to reach an effective tumor containment 1 2. 
Among different types of lung cancer, the non-small cell lung cancer (NSCLC) accounts for 
approximately 85% of all cases and is predominantly comprised of lung squamous cell carcinoma 
(LSCC) and adenocarcinoma (LADC). LSCC and LADC can be distinguished by their histopathology, 
biomarkers, gene expression patterns, genomic alteration, and response to therapies. The 
composition of immune microenvironment differs between LADC and LSCC and it is becoming 
important decipher the function of each cells populating the TME to better understand the role of 
them in tumor initiation and progression and to fully exploit the potential of the novel cancer 
treatment immunotherapies 3. 
Depending on the stage, histology, genetic alterations and patient’s condition, the treatment 
approaches in NSCLC usually include surgery, radiotherapy, chemotherapy, molecularly targeted 
therapy, or immunotherapy. Surgical approach is effective only in patients with early stages, 
whereas more advanced diseases are candidate for non-surgical treatment. Although 
chemotherapy is appropriate for many patients with lung cancer, there is a sense that the use of 
traditional approaches have reached a therapeutic plateau. Increased understanding of cancer 
biology has revealed pathways to be targeted for therapeutic purposes. These include mutated 
tyrosine kinase receptor (such as EGFR and ALK), vascular endothelial growth factor (VEGF), or 
altered PI3K/AKT/mTOR, RAS/MAPK and JAK-STAT pathways which regulate various cellular 
processes including cell cycle, apoptosis, protein synthesis, among others 4. Nevertheless, while 
target therapy in NSCLC has provided disease control, the tumors often develop drug resistance. 
Discover other mechanisms of resistance and develop combinational therapies are essential to 
improve the treatment outcomes 5. In the last few decades, immunotherapies, based on the idea to 
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stimulate the immune system to overcome the cancer progression, became an important part of 
treating different types of cancer, including lung cancer 6 7. 
 
1.1. Cancer immunoediting and immunity cycle 
In cancer, immunosurveillance is a term used to describe the processes by which cells of the immune 
system look for and recognise pre- or cancerous cells in the body. This concept was proposed in 
1909, but only recently demonstrated with the development of gene targeting and transgenic 
mouse technologies 8. The last fifteen years have seen a re-emergence of interest in cancer 
immunosurveillance and a broadening of this concept into one termed cancer immunoediting to 
include the ability of cancer to finally escape from immune system (Fig. 1.1).  A deeper knowledge 
of the immune biology of cancer immunosurveillance and immunoediting will hopefully stimulate 
development of more effective immunotherapeutic approaches to control and/or eliminate human 
cancer.  
 
Figure 1.1. Cancer immunoediting. Normal cells that undergo different alterations can be recognized and eliminate by immune system. 
This is known as elimination phase (or immune surveillance) organized by innate and adaptive immune cell subsets that through the 
release of molecules (such as IFNs, Perforin, TRAIL among others) can eliminate nascent tumor cells. Tumor cells that survive to 
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immune elimination but are not able to overcome the immune system and become clinically evident characterized the equilibrium 
phase. However, cancer cells can escape the immune system because of the reduced immunogenicity and a large number of 
immunosuppressive mechanisms to shut down the antitumor immune response leading to the appearance of symptoms 9.    
One of the main question concerns how the cells of the immunosurveillance network distinguish 
between a nascent or established tumor cells, from normal cells, which represent the first step of 
the cancer immunity cycle 8.  
Tumor cells are genetically unstable, a feature that promotes accumulation of mutations and 
generation of neoantigens that can be recognized by the immune system in the context of major 
histocompatibility complex (MHC) molecules 10 11 12. Since the first human tumor antigen was 
identified in 1991, many tumor antigens have been identified and segregated into five categories: 
1) differentiation antigens, 2) mutational antigens (e.g. abnormal forms of p53), 3) overexpressed 
or amplified antigens, 4) cancer testis antigens and 5) viral antigens 13 14 15 16 17 18 19. 
Thus, even at early stages of tumorigenesis, the cells that undergo transformation might express 
distinct tumor-specific markers and generate pro-inflammatory danger signals that initiate the 
elimination phase, first of cancer immunoediting process, in which both adaptive and innate 
immune cells play a critical role. During the tumor formation, effector cells such as macrophages, 
DCs, NK, NKT and T cells are recruited and activated by inflammatory cytokines released by tumor 
cells and stromal cells in the TME. The activated immune cells, therefore, start to produce molecules 
that mediate the killing of cancer cells (including IL-12, IFN-, Perforin, Fas-L and TNF-related 
apoptosis-inducing ligand-TRAIL) 20 21 22 23 24. Moreover, several cell surface molecules expressed on 
tumor cells have been identified as ligands that bind receptors on immune cells inducing their 
activation. For example, the engagement of NKG2D receptor (expressed mostly on NK cell, NKT cells 
and  T cells) with its ligands on cancer cells (which are induced in response to cellular stress, DNA 
damage or inflammatory milieu), leads to the release of granules containing perforin and granzyme 
that induce cell lysis and elimination of mutated tumor cells 25 26. Evidence shown that mice lacking 
NK cells develop spontaneous tumors supporting the important role of those cells in 
immunosurveillance 22. 
Among immune cells, the professional antigen presenting cells (APCs) which include macrophages, 
B cells and dendritic cells (DCs), carry out an essential role in the elimination phase. The most 
specialized class of APC is composed by DCs which represent the interface between innate and 
adaptive immunity. DCs are able to recognize and present endogenous and exogenous tumor 
associated antigens (TAA) to T cells usually in lymphoid organs in the context of MHC molecules, 
resulting in priming and triggering of an effector T-cell response against cancer 27. Antigens 
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presented on MHC class II molecules are recognized by CD4+ T cells that acquire regulatory 
functions, instead antigens presented on MHC class I molecules are recognized by CD8+ T cells with 
cytotoxic properties (CTLs). Once activated, T cells rapidly proliferate and migrate into tissues to 
carry out their effector responses. This process must be accompanied by signals such as 
proinflammatory cytokines that support the effective action of immune system in order to avoid 
antigen tolerance 28.  
Among different subsets of CD4 T cells, the Thelper1 cells are the principal weapons against cancers 
which are able to orchestrate the beginning and maintenance of the adaptive immune response: 
not only these cells help the antibody responses B cell-mediated, but also mediate the activation 
and expansion of CD8 T cells and are necessary for establishment of effective CD8 T cell memory 29 
30 31 32. Direct CD4 T cells cytotoxic activity on tumor cells presenting tumor associated antigens on 
MHCII molecules has been shown in some cancer patients 33. However, as most tumor cells do not 
express MHCII molecules and CD4+ T helper1 cells can promote the rejection of MHCII-negative 
tumors 34 35, much of their action in cancer has been attributed to the production of cytokines such 
as IL-2, IL-12, TNF- and IFN- associated with inhibition of tumor cell proliferation and activation 
of other immune cells including DCs, macrophages, NK cells and CD8 T cells 36 37 . Nevertheless, 
activated CD8+ T lymphocytes, thanks to their capacity to recognize tumor cells presenting TAA on 
MHC class I molecules and directly kill them via release of effector molecules (e.g., granzyme A/B, 
perforin) or induction of FasL-mediated apoptosis, play the prominent role in cancer 38 39 40. CTLs 
also are able to release IFN- and TNF- to induce cytotoxicity in cancer cells. Thus, the infiltration 
of tumors by cytotoxic CD8+ T cells (hot tumor) is considered as beneficial for the survival of the 
patient and related to a better response to immunotherapy than CTL-low one (referred as cold 
tumor) 41 42 43.  
The resultant killing of cancer cells induce the release of other tumor associated antigens that allow 
to restart the cancer immunity cycle (Fig. 1.2) 44  45.  
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Figure 1.2 The cancer immunity cycle. A series of stepwise events leading the activation of T cell response against cancer cells is named 
cancer-immunity cycle. The first step (1) is characterized by the release of cancer cell antigens that are processed by antigen presenting 
cells (APCs) including dendritic cells (2). The migration of APCs into the lymph nodes allow the priming and activation of cytotoxic T 
cells (CTLs) (3) that acquire effector functions and the ability to reach the tumors site (4-5). Here, the CTLs are able to recognize antigen 
presented on major histocompatibility complex (MHC) class I molecules by cancer cells (6) and kill those cells (7) that induce the release 
of other tumor associated antigens to sustain the cycle 45. 
However, the concept that a tumor can evolve to exist in the presence of an active immune system 
is well established and central to understand the tumor immunity. The phase where tumor cells, 
that have survived the elimination phase, are in equilibrium with the immune system, is refers as 
equilibrium phase. This state of dormancy is maintained by the immune system, which does not 
eliminate totally the tumor cells, but prevents tumors growing. This phase is thought to represent 
the longest of the three phases of tumor development. Indeed, cancer symptoms can occur many 
years after initial transformation. At some point, tumor cells can escape this period of equilibrium 
using two main strategies: avoid the immune recognition and induction of an immunosuppressive 
tumor microenvironment (TME). In fact, the first phase of elimination selects the proliferation of 
cancer cell variants that are less immunogenic and therefore less visible to immune detection. Lack 
of sufficient or suitable neoantigens leads to impaired formation of tumor-reactive T cells. 
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Moreover, even if a tumor expresses sufficient immunogenic antigens, immune detection depends 
on the capacity to present antigen in the context of a peptide-MHC complex. Tumors that lose MHCI 
expression or acquire defects in antigen presentation may escape immune-mediated elimination 46 
47 48 49. Tumor-intrinsic mechanisms of immune evasion include epigenetic changes and activation 
of different oncogenic pathways that allow tumor cells to escape from immune surveillance by 
impair the anti-tumor immune response 50. For example, loss of STK11/LKB1 in the setting of an 
oncogenic K-Ras mutation promotes production of IL-6 which decrease T cell infiltration and was 
associated with higher levels of T-cell exhaustion markers (PD-1, CTLA-4, and TIM-3) 51. In addition, 
cancer cell-derive factors instigate an immune-tolerant TME by secretion of suppressive molecules 
(IL-10, TGF-, prostaglandin E2 or VEGF), by expression of inhibitory checkpoint molecules (PD-L1, 
CTLA-4) and by induction of the recruitment of immune-suppressive subsets through the release of 
chemokine such as CCL2, CSF1, CCL5, CCL22, CXCL5, CXCL6 among others 52 53. Combined, these 
strategies result in a complex and efficient machinery for immune evasion 44. 
Growing evidence showed that tumor-associated immune cells act in concert to both control and 
promote tumor formation 54 55 45. It is true that, during the phase of elimination, NK cells exert a 
tumoricidal role. Moreover, through the secretion of CCL5 and XCL1 those promote the recruitment 
of cDCs to the TME, resulting in increased priming and activation of anti-tumor T cells stimulating 
the overall effector immune response. Additionally, the reciprocal interplay between NK cells, 
effector T cells and anti-tumor macrophages by the secretion of IFN- and TNF- at the tumor site, 
boosts the differentiation of CTLs, increase macrophage phagocytosis, increase the recruitment of 
cytotoxic cMET+ neutrophils and enhances the cytotoxic ability of NK cells 56 57. However, once the 
tumors have escaped from initial tumoricidal immunity, the immune cells are influenced to acquire 
a pro-tumorigenic role and different strategies are used by cancer to tip the balance toward immune 
tolerance, with the TAMs, TANs and tumor-associated T regs as key orchestrators of this process 28.  
The purpose of immunotherapy is to overcome the negative feedback mechanisms that lead to 
immune suppression and to sustain the cycle of immune system to achieve durable anti-cancer 
immune response leading to eradication of cancer. For the above reasons, fully understanding of 
which are the players in the TME and the process involved in the suppression of immune system is 
mandatory 45 58. 
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1.2. The modern immunotherapies target dysfunctional T cells 
Ten years ago, before the era of immune checkpoint inhibitors (ICIs), the solid tumor 
immunotherapy was based on cytokines such as interleukin-2 (IL-2) or alpha-interferon or cancer 
vaccines that were poorly effective and highly toxic 59. The discovery that T cell activation requires 
co-stimulatory signals beside antigenic stimulation through the T cell receptor, and the 
identification of co-inhibitory signalling pathways that negatively regulate T cell activation, provided 
key insights into the complex network of interactions that control the balance between T cell 
activation and tolerance. In normal condition, the co-inhibitory pathways prevent aberrant or 
chronic activation of the immune system and maintain the immune homeostasis. However, these 
pathway can be used by cancer to damper anti-tumor T cell responses and promote immune escape 
60 61. Key players of co-inhibitory signalling are CTLA-4 and the PD-1/PD-L1 pathways 62: the current 
FDA-approved immune check point blockade therapies target these molecules and are now use for 
the treatment of a broad range of tumor types including melanoma, non-small cell lung cancer, 
renal cell carcinoma and hepatocellular carcinoma (Fig. 1.3) 63.   
 
 
Figure 1.3 Immune checkpoint blockade. The binding between B7 ligands (CD80/CD86) expressed on antigen-presenting cells and 
CD28 receptor on naïve T cells leads to T cell amplification and immune response. Alternatively, binding of B7 ligands to CTLA-4 
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expressed on T cells induces suppression of their activity. PD-L1 molecule, often expressed on tumor cells, leads to the anergy of 
activated effector cells through the bind with its receptor PD-1 expressed on those cells. Pharmacological inhibition of immune 
checkpoints with monoclonal antibodies (CTLA-4 inhibitor or PD-1/PD-L1 inhibitor) restores antitumor activity and relieves 
immunosuppression 64. 
In 2011, the first antibody blocking CTLA-4 (ipilimumab) was authorized, rapidly followed by the 
development of monoclonal antibodies targeting PD-1 (pembrolizumab and nivolumab) and PD-L1 
(atezolizumab and durvalumab) 65. Even if both CTLA-4 and PD-1/PD-L1 checkpoint inhibitors have 
resulted, when compared to conventional chemotherapies, in increased patient survival in a 
numbers of studies, including melanoma, renal cell carcinoma, squamous cell carcinoma and non-
small cell lung cancer 7 66 67 68, only a fraction of patients benefit from these therapies and severe 
immune-related adverse events were observed 69 70 66 71 72. Thus, a full understanding of how 
checkpoint blockade works will be critical for widely effective anti-tumor responses.  
CTLA-4 was the first negative regulator of T cell activation identified. Upon T cell activation, it is 
immediately upregulated to damp TCR signalling through competition with the costimulatory 
molecule CD28 for the B7 ligands (CD80 and CD86). The binding between CTLA-4 and B7 ligands 
leads to degradation of ligands needed for co-stimulation and secretion of other inhibitory signals 
which block T cell proliferation and induce anergy and tolerance in both sites of T cell priming (e.g., 
secondary lymphoid organs) and peripheral tissues 73 74. In addition, CTLA-4 can modulate T cell 
activation also through extracellular mechanisms often mediated by its expression on Treg cells 75. 
Its expression in tumor lesions on infiltrating Treg or exhausted conventional T cells as well as tumor 
cells themselves has been associated with decreased survival in nasopharyngeal carcinoma and in 
non-small cell lung cancer 76 77 and due to its negative role on T cell activation has become a target 
for immune checkpoint blockade.  
The exact mechanism by which anti-CTLA-4 antibodies induce an anti-tumor response is unclear 
although seems that CTLA-4 blockade significantly decreases the competition for B7 co-stimulatory 
ligands promoting tumor rejection through an expansion of effector T cells within TME 78. In 
addition, CTLA-4 blockade can induce the Treg depletion and consequently reduce Tregs-mediated 
suppression of immune response as observed in melanoma and other types of cancer 79 80 74. 
Moreover, upon blockade of CTLA-4, antigens that are not normally sufficient to generate an 
effective T cell response may be allowed to emerge due to the broadening of TCR repertoire as 
effect of therapy 81.  
The increased knowledge of negative T cell regulation pathways allowed to discover a second target 
for cancer immune blockade which is represent by PD-1/PD-L1 axis. In normal condition, this 
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pathway is useful to minimize tissue damage and maintain peripheral tolerance. The interaction 
between PD-1, that is expressed on a variety of immune cells, especially on T and B lymphocytes 
upon activation, as well as on suppressive Treg, and its ligands PD-L1 and PD-L2, directly regulates 
TCR signalling to attenuate T cell activity 82. Upon ligation, PD-1 reduces glycolysis and 
simultaneously promotes fatty-acid oxidation and lipid catabolism inducing anergy 83. The ligands 
for PD-1 are expressed on APCs and on different cells in nonlymphoid tissues in response to 
inflammatory cytokines (such as IFN- and TNF-) or tumorigenic pathways, and have been also 
found on many different tumor types associated with tumor escape and poor prognosis 84 85 86 87. 
To overcome this regulatory mechanism and promote an effective antitumor response, antibodies 
targeting this pathway have been developed. It has been shown that PD-1 blockade can principally 
induces reinvigoration of CD8 T cells by pharmacologically prevent PD-1 mediated attenuation of 
TCR signalling resulting in release of inflammatory cytokines and cytotoxic granules that lead to 
elimination of tumor cells 88. In addition, blockade of PD-1 signalling axis can reverse the associated 
metabolic reprogramming to an extent, mediating T cell reinvigoration 89. However, the precise 
mechanism of enhanced anti-tumor response PD-1 mediated is not fully understood. For example, 
although PD-1 blockade primarily leads to the expansion of CD8 T cells, it is known that CD4 T cells 
are required for effective responses to these immunotherapy 90. Moreover, it has been 
demonstrated that also antibodies targeting PD-L1 can induce immune tumor rejection. The efficacy 
of these molecules, similarly to PD-1 blockade, is mainly due to the block of PD-1/PD-L1 interaction 
that extend the activation of T cells in the TME 63. 
A critical point is that PD-1 is a marker of activated T cells of which exhausted T cells are a subset. 
Exhausted T cells undergo transcriptional, epigenetic, and metabolic changes that limits T cell 
activity in presence of chronic antigen stimulation and acts to preserve T cell clones that would 
otherwise perish due to death cell signals in the TME. It was shown that many features of exhausted 
CD8 T cells are associated with differential expression of transcription factor including T-bet (T-box 
expressed in T cells) and EOMES (eomesodermin) 91. Early effector CD8 T cells gradually increase T-
bet expression to become terminally differentiated effectors, whereas memory CD8 T cell increase 
the expression of EOMES e downregulate T-bet expression. Moreover, in chronic stimulation as in 
tumors, the overexpression of EOMES has been linked to execution of exhaustion program rather 
than generation of memory CD8 T cells 92 93. Thus, exhausted T cells are a heterogeneous population 
with altered or reduced functions and high levels of expression of inhibitory receptors (such as PD-
1, TIM3, LAG3, CTLA-4 and TIGIT), that do not involve the complete absence of function. Exhausted 
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T cells can produce effector molecules, including inflammatory cytokines and granzyme, and exert 
some control over tumors 94 95. Due to the role of co-inhibitor receptors in anergy of T cells, targeting 
these molecules has become a promising approach to treat tumors. However, evidence shown that, 
for example, PD-1 blockade may not be sufficient to functionally restore T cells once they reach a 
threshold level of exhaustion and the efficacy of these approach is still limited to the little 
knowledge of downstream signalling pathways that lead to the exhaustion program 96 97 98.  
Nevertheless, immune checkpoint blockade of CTLA-4 and PD-1/PD-L1 axis removes inhibitory 
signals of T cell activation, which enables tumor-reactive T cells to overcome regulatory mechanisms 
and mount an effective antitumor response 99 100. Consistent with the understanding that PD-1 axis 
and CTLA-4 attenuate T cell activation through different mechanisms, combination of PD-1/PD-L1 
and CTLA-4 blockade improves therapeutic efficacy as compared with either monotherapy 101 102.  
However, since ICI action mechanism relies on the inhibition of the physiological brake of immune 
activation, they often have off-target effects resulting in immune-mediated inflammation and 
autoimmune responses in diverse organs or tissues 103 104.  
Numerous currently studies on predictive biomarkers (that are focused on immune cell infiltration, 
PD-L1 overexpression, neoantigen clonality, mutational landscape, miRNA, and others) will help to 
identify, in the future, responders from non-responders and to avoid unnecessary adverse effects.  
As an example, the current guidelines for NSCLC patients recommend to test for expression of PD-
L1 before the use of PD-L1 inhibitors105. The biomarkers already approved, only marginally help to 
stratify responder and non-responder patients, underlying the need of further studies 106 107.   
Besides improving patient’s stratification, a second important goal is to improve efficacy of immune 
blockade treatments. The overall response rate to these agents is usually low and some patients 
who do have tumor regression initially, start losing that response over time supporting the existence 
of mechanisms of resistance to checkpoint inhibitors 108. Therefore, a comprehensive exploration 
of the causes of immune drug resistance will help identify target to overcome limitations. 
Several studies shown that both cell-autonomous (related on the inherent characteristics of tumors 
cells)  and non-autonomous (mainly emanated from the tumor microenvironment) mechanisms can 
causes tumor resistance to ICIs 109. 
The presence of neoantigens on mutated tumor cells boosts anti-tumor T cell response and 
improves treatment efficacy. Evidence suggests that these therapies are more effective for patients 
who already display effective anti-tumor immune processes prior to therapy 110 111 7. Tumors with 
increased tumor infiltrating lymphocytes (TILs) exhibit improved immune-mediated elimination of 
 15 
tumor cells and the presence of TILs in various malignancies can be used as potent predictive 
biomarker for response to ICIs 112. However, the selective pressure caused by checkpoint inhibitor 
treatment may select for non-immunogenic variants that survive treatment and replace the initial 
population 113 114 . For example, in NSCLC acquired drug resistance was associated to the loss of 
neoantigens upon PD-1 or combined PD-1/CTLA-4 treatments 115. Acquired resistance may be 
caused also by tumor antigen presentation defects. For example, loss of antigen-presenting 
machinery components such as beta-2-microglobulin and human leukocyte antigen (HLA) is an 
important mechanism to avoid antigen processing and presentation by tumors and develop 
resistance to ICIs 116. Loss of HLA gene is found in 40% of NSCLCs resulting in a loss of MHC-I-peptide 
presentation which has been associated with resistance to immunotherapy 53.  
Moreover, epigenetic changes and abnormal activated carcinogenic pathways in tumor cells have 
been also associated with both innate and acquired resistance to ICIs. These include activation of 
Wnt/b-catenin signal that prevents the activation of de novo anti-tumor immune response 117, 
deletion of PTEN suppressor gene that increases the resistance of tumor cells to the cytotoxic effect, 
and activation of MAPK signalling that promotes the expression of immunosuppressive cytokine (IL-
6 and IL-10) 118 119. In addition, mutation in key intermediate components of interferon signalling 
pathways (such as JAK/STAT and IFNGR) also leads to resistance to ICIs 109 120 114. A disruption in 
tumor cell responses to IFN- signalling can prevents the induction of PD-L1 expression and thereby 
render its blockade ineffective 119.  
Worth noticing, also tumor-extrinsic mechanisms, which involve stromal or immune cells or other 
systemic influences (host microbiota) acting in concert with cancer cells, can promote tumor growth 
and resistance to ICIs 121 50. High levels of immune suppressive cytokines (such as TGF-, IL-6, TNF), 
angiogenic factor (such as VEGF and ANG2) or metabolites and recruited immune suppressive cells 
(e.g., TANs, TAMs, MDSCs and regulatory T cells) can nullify the impact of tumor-specific T cells and 
influence ICIs efficacy 121 113. As an example, PD-L1 themselves expresses on stromal cells adjacent 
to tumor could contribute to resistance especially in less immunogenic tumors 122 123. 
Collectively, these findings highlight that the success of immunotherapy relies on integration of all 
arms of the immune system and there is the striking need to overcome resistance by targeting 
putative mechanisms of immune evasion within the TME all in the effort to provide long-lasting 
disease control to more patients 124. Many clinical trials are currently ongoing with novel immune-
therapeutic agents (targeting LAG3, TIM3, TIGIT and VISTA), usually in combination with anti-CTLA-
4 or anti-PD-1/PD-L1 antibodies 125. 
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However, it is only through an enhanced understanding of the tumor-immune interaction and its 
modulators (e.g., tumor microenvironment, tumor heterogeneity and patient microbiome) as well 
as discovering the mechanisms of clinical resistance to ICIs that it will be possible to design effective 
therapeutic combinations 126.  
 
1.3. Mature and active dendritic cells as key subset to achieve elimination of cancer 
cells 
Evidence clearly shown that many tumors express antigens that can be recognized by effector CD8 
T cells leading to elimination of cancer cells. However, interactions between naïve T cells and 
professional antigen presenting cells (APCs) in the lymph nodes are crucial for initiating cell-
mediated adaptive immune responses 127. APCs are cells that can process a protein antigen, break 
it into peptides and present them in conjunction with MHC molecules on the cell surface to interact 
with appropriate T cell receptors (TCRs) in the lymphoid organs. Professional APCs includes 
macrophages, B cells and dendritic cells. Among them, dendritic cells are the most efficient in 
activating the immune response, having an important role in induction and maintenance of 
tolerance, but also in anticancer immune responses.  
In normal conditions, DCs are in immature or semi-mature states in the periphery where they take 
up and process self-antigens to maintain self-tolerance. On the other hand, after recognition of 
exogenous and endogenous danger signals by pattern recognition receptor and sensor for danger 
molecules, DCs undergo full maturation. This process is characterized by a down-regulation of 
antigen capture activity, increased expression of MHC and co-stimulatory molecules and cytokines, 
and up-regulation of CCR7 receptor to migrate to lymph nodes where mature DCs can present the 
processed-antigen to naïve T cells, inducing their activation 128 129. Many subsets of DCs with specific 
functions and morphology and localization have been described including Langerhans cells, 
monocyte derived DCs, conventional (cDCs) and plasmacytoid DCs (pDCs) 130. The most studied and 
relevant for anti-cancer responses are the conventional tissue-resident DCs which consist of two 
functionally specialized subsets: the type 1 cDCs (cDC1s) that excel in the priming and cross-
presentation of cell-associated antigens to CD8+ T cells, and type 2 cDCs (cDC2s) that are more 
potent at driving CD4+ helper T cell responses 131. Moreover, thanks to their unique ability to cross-
present extracellular antigen on MHC class I to CD8+ T cells, cDC1s are essential for initiation of anti-
tumor responses 43.  
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Mature and active tumor-infiltrating cDCs (TIDCs) play a pivotal role in the TME and are mostly 
associated with better prognosis and survival in different type of cancer, including breast, lung, 
renal, gastric and ovarian cancers 132 133 134. Not only DCs mediate the activation in lymph nodes and 
consequent migration of effector cells at the tumor site 135 136 137 138, evidence shown that they drive 
the expansion of tumor specific CTLs by directly presenting tumor-associated antigen to T cells in 
the TME 139 140 141. Some data revealed that increased myeloid cell commitment to cross-presenting-
DC lineage and activation of intra-tumoral DCs enhance the clinical response to checkpoint 
inhibitors 142 143. Moreover, even if pDCs represent a small population, evidence shown this subset 
mediates tumor killing through the release of TRAIL and granzymes or by inducing activation of NK 
cells and cytotoxic T cells 144 145 146. 
However, within the TME, cancer cells promote tumor growth, evade immune surveillance and 
confer resistance to immunotherapies by different ways which include impairment of DCs functions 
and their recruitment 147. As an example, the secretion of prostaglandin E2 by cancer cells impairs 
the activation of tumor-associated NK cells and consequent NK cell-dependent DCs recruitment 148. 
Moreover, despite the presence of DCs in TME and their potential in generating an anti-tumor 
response, TIDCs are often defective 149 150.  
In the last few years, many tumor-derived mediators (e.g., VEGF, TGF-, IL-10, M-CSF, IL-6, IL-2) have 
been identified as suppressor of dendritic cell functions. For example, vascular endothelial growth 
factor (VEGF) in the TME can impair both dendritic cell functions and maturation from 
hematopoietic precursors 151 152 153 154 132 155. Also metabolites and physiological stimuli such as lactic 
acid can influence DC phenotype and functions 156. The upregulation of microRNAs (such as miR-16-
1, miR-22, miR-155) or transcription factors (such as STAT3) have been associated with induction of 
apoptotic signaling pathways 157 and impairment of DCs maturation, thereby blocking their 
responsiveness to local danger signals 158. Moreover, immune suppressive molecules such as PD-1, 
PD-L1 and TIM3 expressed in the TME result in an impaired antigen presentation capacity of 
dendritic cells. Studies regarding different type of cancer including melanoma and ovarian cancer 
showed that blockade of these molecules can improve the ability of TIDCs to activate T cells 159 160 
161 162.  
Thus, defective dendritic cells are often characterized by an aberrant maturation, with insufficient 
expression of MHC class I and II and co-stimulatory molecules 163. Therefore, immature, or not-fully 
mature DCs conditioned by the TME, results in tumor tolerance and expansion of T regulatory cells 
leading to a suppression of immune system. Moreover, defective TIDCs create an 
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immunosuppressive environment by induction of anergy of effector T cells through different 
mechanisms which include the production of inhibitory molecules and immunosuppressive 
cytokines such as arginase I (ARG1) and indoleamine 2,3-dioxygenase (IDO) impairing T cell 
proliferation and responsiveness to antigens presented by TIDCs 164 165 166 167.  
Alteration of DCs is an essential element of tumor-mediated immune suppression that leads to 
tumor immune escape, therefore, target the pathways that paralyze TIDCs appears to be a 
promising approach to improve cancer treatments 168. Abnormal accumulation of lipids is one of the 
major mechanisms for DC disfunctions that could be mediated by PMN-MDSC 169 170. However, the 
precise molecular mechanisms that interfere with behaviors of DCs have not been fully elucidated 
and a second gap-in knowledge is the limited understanding of immune suppressive factors that 
target DCs in the TME, for these, further studies are needed. 
 
1.4. Non-malignant cells in the TME as possible target for immunotherapy 
As described before, leukocyte infiltration into tumor tissue and recognition of malignant cells is 
necessary for a successful immunosurveillance of tumors. Cytotoxic CD8 T cells and CD4 Thelper1 
cells represent the most efficient subsets in this process, however, in the TME, different 
mechanisms organized by various population including cancer cells, immune cells and their 
associated cytokines and metabolites, induce T cells suppression, aspect that leads to cancer 
immune escape 171. Therapies including immune checkpoint inhibitor that subvert the dysfunctional 
status of T cells already exist, however, due to their low effectiveness, the discovery of new target 
to disrupt the immune-inhibitory mechanisms will offer the possibility to restore antitumor 
immunity and eradicate cancer cells.  
Variability in leukocytes infiltrate and their contradictory role in promotion or suppression of anti-
cancer immune response have been described across different tumor types and is dependent on 
reciprocal interactions between the tumor and the host. Indeed, the tumor microenvironment is a 
specialized niche composed of tumor cells and the stroma, often characterized by hypoxia and 
vascular abnormalities that correlate with metabolic reprogramming of cancer cells (known as 
Warburg effect) 172 173. In solid tumors, the stroma is composed by the extracellular matrix (ECM) 
and stromal -nonmalignant- cells that include fibroblasts, endothelial cells, pericytes and infiltrating 
leukocytes. In normal conditions, the stroma forms a structure that allows the crosstalk between 
those cells, regulates the presence and the distribution of nutrients and waste products and it is a 
scaffold for resident inflammatory cells (mast cells, macrophages, immature dendritic cells) 
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monitoring for invading pathogens and mutated cells. However, the functional and structural 
characteristics of stroma undergo dramatic changes during progression of neoplasia, often 
characterized by chronic inflammation 174 175 176 due to the release of growth factor, pro-angiogenic 
mediators and cytokines, which regulate the leukocytes recruitment and shape their cellular fate 177 
178 179.   
Inflammatory immune cells are essential players of cancer-associated inflammation, which is 
present at different stages of tumorigenesis and is a critical hallmark of cancer. During the early 
stage of tumor development, the infiltration of leukocytes and the subsequent inflammation due to 
release of pro-inflammatory mediators can, in certain cases, eliminate tumor cells and prevent 
tumor development (immunosurveillance). For example, it has been recently demonstrated that 
some tumor lesions including ovarian cancer, breast cancer and non-small cell lung cancer, can 
display ectopic lymphoid-like structures called tertiary lymphoid structures (TLSs). The genesis of 
these structures is related to the local production of CXCL13 and IL-17 by lymphocytes or stromal 
cells and are associated with a favourable outcome. In fact, those structures contain T cells-rich zone 
with mature DCs juxtaposing a B cell, surrounded by plasma cells, thus representing a site for local 
presentation of neighbouring tumor antigens to T cells by DCs leading to an activation and 
proliferation of T and B cells and consequent long-lasting anti-tumor response 180 181 182 183. 
However, it is currently accepted that the chronic inflammation and the consequent aberrant innate 
and adaptive immune response characterizing the established malignancies, contribute to immune 
escape and tumorigenesis by selecting aggressive clones, inducing immunosuppression and 
induction of cancer cell proliferation, angiogenesis and metastasis 184 185 186.  
Beside DCs, T cells and B cells, other leukocytes have been found in the TME of most human cancer, 
including macrophages, MDSCs, and neutrophils. The latter, represent a frequent subset in different 
type of cancer, especially NSCLCs 187 and their role at the tumor site remain controversial and tissue 
context dependent. Thus, the composition of immune landscape is dependent on tumor type and 
constellation of immune-modulating factor in the tissue. How different immune cells are activated 
and recruited to the tumor site and how they interact with each other and with cancer cells are still 
not fully understood and crucial to fully exploit the development of new therapies 188 189. 
Therefore, while most cancer research has focused on acquired mutations in oncogenes or tumor 
suppressor genes, and the most therapeutics are directed against tumor cells, it is now apparent 
that the non-malignant cells in the microenvironment evolve along with the tumor and provide 
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essential support for their malignant phenotype and can represent a target for new cancer therapies 
190. An overview on the most relevant immune suppressive subsets in cancer is described below.  
 
1.5. Immune suppressive behaviour of CD4 T regulatory lymphocytes 
Normal cells that undergo transformation becoming malignant can exhibit antigens on MHCI or 
MHCII molecules as targets for activated effector CD4 or CD8 T cells, respectively 191. Although direct 
tumor cytotoxicity has been described, activated CD4 Thelper1 cells usually mediate anti-cancer 
response by release of cytokines (such as IL-2, IFN- and TNF-) which promote activation of both 
innate and adaptive immune responses. However, other subsets of CD4 T cell exist in the TME, 
including Thelper2 cells, IL17 producing CD4 T cells and T regulatory cells (Tregs), often associated 
to an immune suppressive behaviour 192.  
It has been demonstrated that CD4+ T helper2 lymphocytes can promote tumor growth through the 
production of pro-tumorigenic cytokines such as IL-5 193 194, whereas, IL-17-producing CD4+ T cells 
promote angiogenesis and tumor growth via release of the pro-inflammatory cytokine IL-17 195 196. 
Overall, T regulatory cells are the most powerful inhibitors of anti-tumor immunity and the major 
barrier to successful immunotherapy. High infiltration of Tregs in tumors, and in particular high 
Tregs-CD8 T cells ratio, is associated with the shutdown of the immune system and with a poor 
prognosis in different type of cancer including melanoma, non-small-cell lung cancer, gastric, 
colorectal, breast and ovarian cancer 197 198 199 200 201. Those cells accumulate in the TME in response 
to several mechanisms. Tregs can be recruited in the TME by chemokines (such as CCL1, CCL5, CCL28 
and CCL17/22) produced by dysfunctional immune cells and tumor cells in the TME 202 203 204, or can 
expand in situ in response to cytokines such as IL10 where exhibit their strong immunosuppressive 
capacity by numerous cellular and humoral mechanisms. Through the secretion of inhibitory 
molecules (such as IL-10, TGF-, IL-35, prostaglandin E2 and galectin-1) Tregs induce the apoptosis 
of target cells. Moreover, Tregs lead to immune suppression by the consumption of IL-2 and 
degradation of ATP which are necessary for proliferation and functionality of T cells 205 or by the 
expression of immune checkpoint molecule including CTLA-4, PD-1/PD-L1, TIM3, LAG-3 and TIGIT 
which inhibit priming and activation of T cells 42 198. Moreover, high level of circulating Tregs has 
been associated with higher risk of metastasis in patients with NSCLC, breast cancer and colorectal 
cancer 206 207 208. In conclusion, considering the role of Tregs as key regulator of anti-tumor immune 
suppression, direct (targeting of molecules expressed by Tregs such as CD25, PD-1 and CTLA-4 or 
pathways that are crucial for Tregs survival and function) or indirect (targeting factors in the TME 
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such as VEGF or other immune-suppressive cells, MDSCs and TAMs, that may activate and/or recruit 
Tregs) suppression of Tregs represent a promising anticancer therapeutic strategy, although 
approaches to control these cells require further research 209 210 .  
 
1.6. Tumor-associated macrophages (TAMs) 
Another subset highly represented in TME is composed by macrophages which play a critical role in 
innate immunity and are responsible for defending the host against foreign pathogens. Those 
differentiate from circulating monocytes after extravasation into tissues. Here, macrophages are 
equipped to sense and respond to infections and tissue injuries. Even if there is evidence that TAMs 
contribute to the early elimination phases of nascent tumors orchestrated by T cells and interferons 
211, high-grade tumor associated macrophages (TAMs) correlate with poor prognosis and reduced 
overall survival in different type of cancer, including NSCLC 212 213. In established tumors, cytokines 
(such as IL-4 and IL-13) released from different immune cells (T cells, B cells, eosinophils and 
basophils) or signals originating from tumor cells (TGF-, CSFs) and stromal cells (IL-1) elicit 
alternative activation of TAMs leading to tumor progression 52.  
TAMs are recruited to the tumors by a range of chemokines including CCL2, VEGF, CCL5 and CSF1. 
Here, TAMs play a dominant role as orchestrator of cancer-related inflammation through their 
production of molecules such as IL-6, TNF- among others that support tumor cell survival and 
proliferation 214 215. Moreover, TAMs are able to promote the formation of metastasis by the release 
of growth factor (such as VEGF and EGF), extracellular matrix degrading enzymes (such as 
macrophages-derived metalloproteinases and cathepsins) that promote angiogenesis, remodelling 
of the ECM and epithelial-mesenchymal transition 150 216. In addition, molecules secreted by TAMs 
such as IL-10, ROS, IDO, ARG1 and TGF-, impair the activity of effector T cells and DCs maturation 
and promote the recruitment of Treg cells, leading to suppression of anti-tumor response 150 217 218. 
Moreover, macrophages express ligands of PD-1 and CTLA-4 able to inhibit T cell cytotoxic functions 
and the activation of NK cells 219 220 221 28.   
In conclusion, TAMs significantly contribute to tumor development by induction of angiogenesis, 
chronic inflammation and immune suppression and represent a target for cancer immunotherapy, 
however there are still massive issues and limits that need to be addressed that slow down the 
development of effective therapies 222. 
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1.7. Myeloid-derived suppressor cells (MDSCs) 
Twenty years ago, a new population in cancer patients, named myeloid-derived suppressor cells 
(MDSCs) was described. These cells are an heterogeneous cellular population that comprises several 
maturation states of  myeloid cells that expand during cancer and share the ability to suppress T cell 
responses, induce tumor angiogenesis, metastasis and drug resistance 223. However, new scRNA seq 
data suggest revisiting the concept of tumor infiltrating myeloid cells and overcome the term 
MDSCs.  
At steady-state, progeny of common precursors acquires specific markers and functions of 
circulating leucocytes and progressively lose their ability to self-renew (myelopoiesis). In 
pathological condition, emergency myelopoiesis is induced to provide cells to eliminate potential 
threats (including cancer cells). If these conditions resolve quickly, the balance of myeloid cells can 
be restored, however, in cancer, the chronic inflammation leads to an aberrant and sustained 
myelopoiesis. This results in the accumulation of immature myeloid cells able to induce immune 
dysfunction due to their pathological activation which are morphologically and phenotypically 
similar to neutrophils and monocytes (MDSCs) 224 225. Indeed, in most types of cancers, MDSC consist 
of two main large groups of cells. The most frequent is termed polymorphonuclear (PMN-MDSC) 
which phenotypically and morphologically resemble neutrophils, the second, less frequent, be like 
to monocytes (M-MDSC) 226 227.  
Overall, the ability to suppress anti-cancer responses is a distinctive characteristic of MDSCs. 
Evidence show that MDSCs expansion and activation are influenced by several factors that can be 
produce by cancer cells or by activated T cells and stromal cells (including VEGF, CSFs, TGF-, IL-4, 
IL-13, IFN- among others) 228 and their main feature is the ability to suppress the immune system 
by different mechanisms including upregulation of arginase 1 (ARG1) and nitric oxide synthase 
(NOS) activities and release of reactive oxygen species (ROS) which suppress T cell activities. 
Recently, it has been shown that another mechanism of immune suppression MDSCs-mediated is 
the induction of Tregs through the production of cytokines or direct cell-cell contact 229 230 227. 
Moreover, recent data suggest MPO-driven lipid peroxidation in PMN-MDSC could be a possible 
mechanism of inhibition of antigen cross-presentation by DCs 170. Besides direct immune 
suppressive mechanisms, MDSCs can promote tumor progression by affecting the remodelling of 
the tumor microenvironment, and inducing tumor angiogenesis and metastases 231 232. Thus, MDSCs 
are a critical element of the immune suppressive niche in cancer also related to resistance to 
immune check point inhibitors 233 234.  
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However, one of major unsolved issues is how to phenotypically distinguish MDSCs from neutrophils 
and monocytes in mice and human. Recently, a possible marker of identification of PMN-MDSC in 
humans has been identified and consist of lectin-type oxidized LDL receptor 1 (LOX-1), present on 
PMN-MDSCs but not on neutrophils. If confirmed in further studies, LOX-1 can be used for direct 
identification of PMN-MDSC in blood and in patients. On the contrary, the phenotypic distinction in 
mice is still challenging 235 and whether TAN activity can be attributed to MDSC remains a matter of 
debate 236. Therefore, targeting of MDSCs could be promising for new cancer treatments and for 
this purpose a better characterization of this population is needed. 
 
1.8. Heterogeneity of neutrophils in homeostatic conditions 
Neutrophils are the most abundant circulating leukocyte, in human representing 50-70% of all 
leukocytes, and are the first responders to sites of infection and tissue damage. Those cells display 
an enormous functional plasticity and their primary function is to mediate host defense 237.  
Neutrophils are produced in large numbers in the bone marrow and extramedullary tissues 
(including spleen) from the hematopoietic stem cells that differentiate into granulocyte-monocyte 
progenitors (GMPs). According to current paradigm that classify different stages of granulopoiesis 
on the basis of morphological features (cell size, nuclear condensation and granule content), a 
granulocyte-committed progenitor with proliferative properties deriving from GMPs, develops into 
post-mitotic immature neutrophils and, under control of the granulocyte colony-stimulating factor 
(G-CSF) and granulocytes-macrophage colony-stimulating factor (GM-CSF), into a mature neutrophil 
containing granules and secretory vesicles relevant for their functions 238 239. Recently, single-cells 
RNA sequencing (scRNA-seq) and mass cytometry by time-of-flight analysis (CyTOF) allowed to 
better understand the complete neutrophil-lineage hierarchy from GMPs to mature neutrophil. In 
particular, it has been identified in mouse and human, the so called early unipotent neutrophil 
progenitors (NePs) and pre-neutrophils (preNeus) as proliferative neutrophil-committed bone 
marrow-residing cells that are downstream of GMPs and may serve as a proliferative pool that can 
rapidly amplify neutrophils numbers on demand 240 241 242.  
Maturation processes include changes in shape of nucleus and expression of various receptors. As 
an example, the CXCR4 is downregulated, while CXCR2 and TLR4 are upregulated. Indeed, under 
homeostatic conditions, the release of matured neutrophils is tightly controlled through CXCR4 and 
CXCR2 chemokine receptors signaling. The CXCL12 produced by osteoblasts and other bone marrow 
stromal cells binds CXCR4 expressed on neutrophils preventing their release into the circulation, 
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while ligands for CXCR2 such as CXCL1, CXCL2, CXCL5 and CXCL8 produced by endothelial cells 
outside the bone marrow drive their mobilization into the blood 243 244. In peripheral blood, 
neutrophils are short-lived cells which require a constant replenishment from the bone marrow 
precursors 245. It has been showed that the lifespan of circulating neutrophils under steady-state 
conditions is up to 12.5 hours for mouse and 5.4 days for human and may be prolonged in an 
inflamed context 246. Increased numbers of neutrophils are frequent in the peripheral blood of 
patients with various type of cancer, correlating with less favorable prognosis247. Blood-based 
inflammatory parameters, such neutrophils to lymphocyte ratio (NLR) has been reported to predict 
the prognosis in solid tumors. Interestingly, high NLR has been associated with a poor prognosis in 
lung cancer patients 248. In absence of inflammation signals, neutrophils in the circulation rapidly 
undergo aging. This term is used to describe changes in phenotype and molecules expression from 
mature neutrophils that enter the circulation, to aged neutrophils. Thus, circulating neutrophils 
progressively lose their granule contents, NET-forming capacity and ability to migrate into inflamed 
tissues, limiting their tissue-damaging potential 249 250. Moreover, several studies showed that aged 
neutrophils downregulate the expression of CXCR2 and CD62L and upregulate CXCR4 driving their 
homing back to the bone marrow and consequent elimination through phagocytosis by 
macrophages. The aging process is regulated by gut microbiota and is controlled by neutrophils 
themselves through a cell-autonomous transcriptional program following circadian oscillation over 
time 250 251. Recently, scRNA-seq analysis, allowed to identify a subset of circulating neutrophil, 
observed also in tumors, characterized by the expression of interferon-stimulated genes that may 
represent a primed population to fight infections 252 253. 
Yet, neutrophils in the circulation could be mobilized to sites of inflammation or infection by a 
complex milieu of chemokine through a process named leukocytes adhesion cascade: glycoprotein 
ligands on neutrophils bind to adhesion receptors on activated endothelial cells nearby the affected 
site, leading to transmigration of neutrophils into peripheral tissues 254.  
Once in the tissues, neutrophils are able to capture and destroy invading microorganisms through 
different mechanisms: 1) phagocytosis and intracellular degradation, 2) release of noxious 
substances including granule-derived compounds like antimicrobial peptides, reactive oxygen- 
(ROS) and nitric oxide- species (NOS) and 3) release of nuclear material in the form of extracellular 
fibrillary networks termed neutrophils extracellular traps (NETs) 247. Finally, neutrophils undergo 
apoptosis and are cleared through phagocytosis by resident macrophages and dendritic cells 255.  
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As mentioned above, neutrophils maturation and release into the circulation is regulated 
predominantly by G-CSF that promotes the differentiation of hematopoietic precursors, induces the 
upregulation of CXCR2 and reduces the expression of CXCR4. The expression of G-CSF is in turn 
regulated through the axis IL-23/IL-17. Phagocytosis of apoptotic neutrophil triggers an anti-
inflammatory response characterized by a reduction in IL-23 by macrophages and DCs leading to a 
downregulation of IL-17 levels produced by T lymphocytes and G-CSF production, finally reducing 
granulopoiesis 256 238 257. Other cytokines have also been implicated in promotion of granulopoiesis 
including GM-CSF, M-CSF, and IL-6. The latter, has a special importance in emergency granulopoiesis 
in response to systemic infection 258 259. 
An open question is whether tissue-specific neutrophil exist. With the exception of the brain and 
gonads, most tissues are actively infiltrated by neutrophils at steady state, at least in mice, 
supporting their homeostatic role within healthy tissues 260 261. As an example, neutrophils found at 
the marginal zone of the spleen are able to induce somatic hypermutation and antibody production 
by B lymphocytes through the release of cytokines such as IL-21 262. In the lung, neutrophils have 
been found in the vascular lumen and in the interstitial space, kept in the tissue by a CXCR4-
dependent mechanism that may facilitate rapid responses to microbial challenges 263. In the lymph 
nodes, neutrophils expressing MHCII molecules have been found in proximity to T cell, suggesting a 
role of those in antigen presentation 264. Moreover, neutrophils that express VEGFR1 are recruited 
to non-vascularized tissues under hypoxia conditions where they are able to promote angiogenesis 
and vascular repair 265 266. Interestingly, this pro-angiogenic subset is similar to one observed in 
tumor supporting vascularization 267. In addition, various subsets of neutrophils with distinct 
properties have been also detected in pathological conditions (such as cancer as described below) 
268.  
Although heterogeneity of neutrophils is now recognized, how different subsets of neutrophils are 
generated, recruited to tissues and the biological relevance of this remain under debate. So far there 
is no evidence for ontogenetically distinct neutrophils and their diversity may be the result of their 
high plasticity in response to environmental signals 269 270.  
 
1.9. Tumor associated neutrophils (TANs) recruitment and polarization 
It has long been known that neutrophils are present in different type of cancer including renal cell 
carcinoma (RCC), colorectal cancer, melanoma and lung cancer and their abundance in the TME is 
in general related to poor outcome 3 271 272 273. High TANs infiltration is associated with a worse 
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response to the conventional chemotherapy and radiotherapy, but also with a poor response to 
more recent immune checkpoint inhibitors 274 275 276.  
Neutrophils with different states of maturity and activation have been found in tumor conditions 
and understanding how neutrophils are mobilized from the bone marrow and influenced by tumor-
derived signals is mandatory to explore their role in tumor progression 277.  
The presence of immature neutrophils in the circulation and in tissues is often the result of 
emergency hematopoiesis induced by tumors. As an example, emergency hematopoiesis has been 
linked to the overexpression of growth factors such as G-CSF observed in different type of cancer 
models such as breast cancer 278 279 280 and in human gastric and colon cancer  281 . Interestingly, 
immature neutrophils having immunosuppressive properties have been detected also in lung cancer 
282 283.  Enhanced levels of G-CSF are induced by pro-inflammatory cytokines released by cancer cells 
themselves or tumor-associated stromal cells. In breast cancer model, IL-1 produced by 
macrophages in the TME elicited IL-17 expression from  T cells resulting in G-CSF production and 
neutrophils recruitment which facilitated immune suppression and pulmonary metastasis 
formation 279. In addition, high levels of IL-17 have been found in breast cancer patients that was 
correlated with shorter disease-free survival and poor prognosis 284 and in human hepato-cellular 
carcinoma (HCC) where it promoted neutrophils recruitment 285. Pro-inflammatory cytokines induce 
also neutrophils polarization. As an example, TGF- is one of the known factors able to polarize 
different subsets of the immune system, including neutrophils 286. It has been demonstrated that 
TGF- within the TME induced the recruitment of TANs and promoted their polarization to pro-
tumoral phenotype in mesothelioma 287. Moreover, TGF--blockade promoted the migration and 
activation of neutrophils with anti-tumoral properties, which decreased tumor growth 287. In 
addition, also TNF has been associated with neutrophil recruitment and tumor progression in 
mouse colorectal cancer 288. Yet, IL-6 produced by mesenchymal stem cells is crucial for the 
recruitment and activation of neutrophils in gastric cancer, enhancing their pro-tumoral polarization 
by activation of STAT3-ERK1/2 pathway 289. On the other hand, evidence showed that other 
cytokines in tumors, such as type I interferon, are related to an anti-tumor polarization of TANs 290 
267 291.  
Moreover, neutrophils polarization can be attributed to tumor physiology. At early stage of 
tumorigenesis in lung and mesothelioma murine cancers, neutrophils showed higher cytotoxic 
activity toward tumor cells, whereas, in established tumors, TANs acquired a pro-tumorigenic 
phenotype 292. Yet, factors released by tumor cells such as MIF (macrophage migration inhibitory 
 27 
factor) 293 or hypoxia, modulated neutrophils lifespan resulting in increased neutrophil survival and 
polarization to pro-tumorigenic behavior 294. Details regarding the lifespan of neutrophils in tumors 
remain to be fully elucidated. Interestingly, in a recent work it has been showed that the glucose 
metabolism upregulated in TANs in a model of lung cancer slowed down their turnover promoting 
the acquisition of a pro-tumorigenic behavior 295. 
Other factors have been related with neutrophils recruitment in cancer. As an example, Wnt ligands 
produced by cancer cells in the TME stimulated the IL-1 production by tumor associated 
macrophages which resulted in immature neutrophils recruitment in breast cancer and subsequent 
metastasis formation 296.  Of note, commensal microbiota has been linked to the production of IL-
1 and IL-23 by myeloid cells which in turn induced IL-17-producing T cells activation resulting in 
neutrophil infiltration and lung cancer development 297. In addition, in melanoma, UV exposure 
triggered the release of high mobility group box 1 (HMGB1) promoting the recruitment and 
activation of neutrophils through toll-like receptor 4 (TLR4) signaling 298. Yet, chronic exposure to 
crystalline silica, linked to inflammation and lung cancer initiation, has been related to neutrophils 
recruitment and enhanced tumor growth through mast cells- and macrophages- leukotriene (LTB4) 
production 299.  
Also, chemokines (i.e., CXCL1, CXCL2, CXCL5, CXCL6 and CXCL8) often upregulated in the TME of 
different type of cancer, play a major role in neutrophil recruitment through the binding with 
chemokine receptors CXCR1 and CXCR2 highly expressed on those cells 300 301 302 303. As an example, 
hypoxia has been showed to induce upregulation of Snail in lung cancer cells that accelerated 
disease progression and CXCL2 expression by neutrophil themselves leading to a cycle 
encompassing neutrophils and Snail to maintain a deleterious tumor microenvironment 304.  
In this current work, we focused on the role of murine chemokine CXCL5 (which share the 80% of 
identity with CXCL6 in human 305) in recruitment of a particular pro-tumorigenic subset of 
neutrophils in lung cancer (as described below). CXCL5 is involved in neutrophils recruitment in 
pulmonary infection and inflammation 306 307 308 and in lung cancer 3 304. In colitis and colitis-
associated colon cancer (CAC), over-expression of CXCL5 accelerated the recruitment of neutrophils 
through the CXCL5-CXCR2 axis, leading to cancer formation 309. Moreover, the human homologous 
CXCL6 (also known as granulocytes chemotactic protein2, GCP-2) has been showed to induce 
neutrophils influx in pulmonary fibrosis in human 310. In addition, up regulation of CXCL6 in small 
cell lung cancer correlated with tumor progression and poor prognosis 311 312 313 and 
pharmacological inhibition of CXCR2 decreased primary lung tumor growth and pancreatic cancer 
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metastasis in mice 314 315. Interestingly, in vivo studies showed that KRAS signaling, often mutated 
in lung cancer, is able to regulate the expression of neutrophils-related cytokines such as CXCL8 and 
CXCL5 316 3. In addition, in human cancer, mutation of KRAS correlates with neutrophils recruitment 
raising the question of whether KRAS alone is sufficient to orchestrate neutrophils recruitment and 
polarization 317. 
Thus, it has been well demonstrated that the tumor promotes the recruitment and polarization of 
neutrophils, however, the dynamics of neutrophils recruitment at the tumor site is not fully 
understood. Intravital multiphoton imaging showed that neutrophils infiltrate the tumor within 3 
hours in a transplanted mouse model and persist for up to 3 days in the TME. Interestingly, the 
motility of peritumoral neutrophils increased when compared to intra-tumoral neutrophils, 
suggesting the presence of different states of polarization within the tumor itself 318. Moreover, in 
early, but not late, NSCLC, IFN and GM-CSF have been showed to drive the differentiation of APC-
like neutrophils with an anti-tumorigenic phenotype 319. For this, in future will be important to 
demonstrate whether neutrophils are polarized before reaching the tumor site or TANs can mediate 
anti-tumor resistance at the initial phase of tumorigenesis, whereas, probably due to their high 
plasticity, during progression of cancer, acquire pro-tumorigenic phenotype contributing to tumor 
progression. 
Thus, many factors have been associated with recruitment of neutrophils at the tumor site and with 
their polarization into phenotypically distinct pro- or anti-tumorigenic sub-populations. However, 
mechanisms of neutrophils polarization are still poorly defined and their role in tumor progression 
remains controversial and strongly dependent on the tumor type, the cellular microenvironment, 
and the constellation of immune modulating factors.  
 
1.10. TANs in tumor initiation and progression 
It is now well established that inflammation play an essential role in initiating tumorigenesis and 
neutrophils recruited in the TME represent a crucial component of this process. It has been shown 
that blocking neutrophils trafficking using CXCR2-deficient mice or antibody-mediated depletion of 
neutrophils prevented tumor formation 320 321 322. In addition, neutrophil-released reactive oxygen 
species (ROS) can cause tissue damage which potentially favors tumorigenesis 323. As an example, 
ROS produced by neutrophils recruited in hepatic parenchyma under inflammation have been 
associated with DNA damage which was sufficient to induce hepatocellular carcinoma 324. Beside 
ROS, other genotoxic DNA substances produced by neutrophils including RNA, NOS, MMP-9, MPO 
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and TGF- can induce DNA instability and neoplasia 325 326 . Also, neutrophil-derived microparticles 
containing pro-inflammatory microRNAs, have been shown to promote DNA breaks and to induce 
lamin B1-dependent replication fork collapse and inhibition of homologous recombination leading 
to impaired colonic healing and neoplasia 327. In addition, different cytokines including IL-8, IL1- 
and IL-6 and growth factors such as EGF, HGF, PDGF, PGE2 released by neutrophils have been 
related to tumor initiation and progression 328 329 330 331. However, the role of neutrophils in cancer 
is still controversial and strongly dependent on the tumor type (Fig. 1.4). 
 
Figure 1.4. Pro-tumorigenic behavior of neutrophils. a) Neutrophils are recruited in the tumor through different mechanisms which 
include tumor-derived growth factor, cytokines, and chemokines. The latter has been associated with mobilization of neutrophils in 
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the pre-metastatic niche. B) neutrophils are able to promote tumor growth by different mechanisms. As an example, neutrophil-
derived factors (NE, BV8, MMP9) promote cell proliferation and angiogenesis leading to metastasis formation. Moreover, circulating 
neutrophils promote the extravasation of cancer cells and consequent metastasis formation. c) Importantly, through the release of 
ARG1, ROS, NO and the expression of immune checkpoint ligands, neutrophils impair T cells activation, leading to immune suppression. 
d) Also, neutrophils induce tumor initiation and progression by inducing genetic instability and by promoting tumor cell proliferation 
and angiogenesis 302. 
 
One of the mechanisms used by neutrophils to promote tumor growth is through the induction of 
angiogenesis, a hallmark of malignant tumors 332 333. In particular, it has been demonstrated that, in 
different mouse models (such as melanoma, pancreatic and squamous cell cancer), tumor-
infiltrating neutrophils expressing proangiogenic factors such as VEGF and MMP9, were able to 
promote the formation of a new blood vessels required for tumors to acquire oxygen and nutrients 
essential for their growth 267 334 335. Moreover, the neutrophil-derived Bv8 protein has been recently 
characterized as a regulator of angiogenesis implicated in the angiogenic switch during neoplasia 
336. Nevertheless, the mechanisms by which TANs induce tumor-angiogenesis are not fully 
elucidated. Evidence of angiogenesis mediated by neutrophils has been observed also in human. In 
vitro studies shown that, upon stimulation, human polymorphonuclear neutrophils (PMN) released 
pro-angiogenic factors (such as VEGF and IL8) which induced sprouting of capillary-like structure 337. 
Interestingly, in human gastric cancer, neutrophils are highly represented and associated with 
MMP9 production which stimulated proangiogenic activity in gastric cancer cells 338. In addition, 
myeloperoxidase (MPO) contained in NETs promoted a pro-angiogenic response in human 
pulmonary endothelial cells by activation of TLR4 signaling leading to proliferation and motility 339. 
Importantly, NETs have been not only associated with tumor-angiogenesis, but also with 
extracellular matrix remodeling, proliferation of tumor cells, and consequent neutrophil-mediated 
invasiveness and metastasis 340. As an example, murine metastatic breast cancer cells trigger NETs 
formation by neutrophils promoting metastasis and lung colonization. Using intravital imaging, NET-
like structures have been observed around metastatic cancer cells in the lung of mice, and blockade 
of NET formation prevented lung metastasis 341. Moreover, NETs were able to protect tumor cells 
from cytotoxicity mediated by CD8 T cells and natural killer cells by wrapping and coating tumor 
cells, favoring tumor growth 342. In addition, the secretion of HMGB1 during NETosis in response to 
surgical stress promoted metastasis in resected liver in mouse and human. In vitro studies suggested 
that the activation of TLR9 pathway in cancer cells in response to HMGB1, promote their adhesion, 
proliferation, migration and invasion properties 343. The neutrophil-dependent metastasis 
formation is also associated with other factors contained in the NETs. It has been observed that, in 
different mouse model (including breast and lung cancer models), NET-derived factors such as 
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MMP9, MMP8, Cathepsin G and NE, which modulate the extracellular matrix (ECM), were able to 
promote tumor cell proliferation and migration 344 341 345. In particular, a study demonstrated that 
neutrophil-derived NE and Cathepsin G degraded the antitumorigenic factor thrombospondin-1 
(Tsp-1) promoting lung metastasis 346.  
Interestingly, several studies showed the ability of neutrophils to engage with circulating tumor cells 
promoting extravasation and subsequent metastasis formation 347 348 349 350. Lastly, neutrophils 
participate to the constitution of the metastatic niche and to the acquisition of metastatic 
phenotype in certain tumor cell type 351. Also, the atypical chemokine receptors (ACKRs) expressed 
on hematopoietic precursor and downregulated during myeloid differentiation may be responsible 
for neutrophil-mediated metastasis 352. 
Beside induction of metastasis, several factors released by neutrophils in the TME have been 
associated with enhanced proliferation of tumor cells and consequent tumor growth 302. As an 
example, neutrophil-derived leukotrienes promoted the expansion of a pool of breast cancer cells 
with high tumorigenic properties favoring lung colonization 353. Moreover, elastase released by 
neutrophils (NE) was able to induce proliferation of cancer cells in a lung adenocarcinoma model 
and in human lung adenocarcinoma cell line. The mechanism of this effect was elucidated in great 
details and it involves access of NE to tumor cells endosomal compartment and degradation of 
insulin receptor substrate 1 (IRS1), promoting interaction between phosphatidylinositol 3-kinase 
(PI3K) and the mitogen platelet-derived growth factor receptor (PDGFR) 354 355. The mitogenic 
activity of NE was also observed in vitro with human mammary epithelial cells through the activation 
of ERK signaling 356 and with esophageal cell line by inducing the release of growth factor such as 
PDGF, TGF and VEGF 357. Also, in vitro studies with human renal cell carcinoma cells showed that 
neutrophils promoted cancer cells proliferation by inducing up-regulation of androgen receptor 
signals 358.  
Another known mechanism that neutrophils used to trigger tumor growth is the induction of 
epithelial to mesenchymal transition that enhance tumor cell migration and invasion ability. A 
recent study revealed that neutrophils in parenchyma of breast cancer patients were able to induce 
epithelial-mesenchymal transition (EMT) of breast cancer cells leading to metastasis formation and 
poor prognosis. Of note, neutrophils in the stroma of breast cancer were not associated with poor 
prognosis, underlying the importance of location-dictated interaction between tumor cells and 
neutrophils 359. Moreover, in pancreatic ductal adenocarcinoma and lung adenocarcinoma patients, 
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neutrophils have been correlated with EMT most likely due to an elastase-mediated degradation of 
E-cadherin leading to a loss of cell-to-cell contact 360 361.  
 
1.11. TANs as suppressor of anti-cancer immune responses 
A further crucial way to promote tumor growth by TAN is via suppression of ongoing anti-cancer 
responses. Several factors released by neutrophils, including ROS, RNA and ARG have been 
associated with suppression of both innate and adaptive immune response 303 287. In particular, 
TANs are mainly described as damper of T cell mediated anti-tumor responses. In a mouse model 
of breast cancer, in a glucose-limited environment, immature neutrophils engaged in oxidative 
mitochondrial metabolism leading to ROS production and nutrient consumption leading to 
suppression of T cell responses 362. In addition, mammary tumor-induced IL-17-producing  T cells 
were shown to drive systemic expansion and polarization of neutrophils to a pro-tumorigenic 
subpopulation characterized by iNOS overexpression and NO production which suppressed T cells 
responses and therefore promoted metastasis in distant organs 279. Of note, NO produced by TAN 
has been shown to promote CD8 T cell apoptosis and consequent tumor-supportive environment 
363. 
Interestingly, pro-tumorigenic polarized neutrophils are able to produce arginase that in turn reduce 
CD8 T cell activation by limiting L-arginine availability in the TME 287. Importantly, production of 
ARG1 by neutrophils impaired T cell responses also in human cancer, including renal cell carcinoma 
and NSCLC 364 365 366. Moreover, recent evidence showed that neutrophil-derived MMP-9 induced 
activation of latent TGF- and consequent suppression of tumor infiltrating T cells in colon cancer 
367. 
It has also been suggested that an altered lipid metabolism in neutrophils may induce immune 
suppression. Recently, a study revealed that neutrophils in different type of cancer in mouse and 
human, upregulated the fatty acid transport protein 2 (FATP2) under GM-CSF stimulation with 
consequent expression of prostaglandin E2 (PGE2), which is involved in suppression of anti-tumor 
CD8 T cell-mediated responses 368. In addition, in patients with NSCLC and head and neck cancer, 
stress of the endoplasmic reticulum (ER) boosted the expression of the lectin-like oxidized LDL 
receptor 1 (LOX1) that triggered an altered lipid metabolism in neutrophils. Expression of LOX1 
converted neutrophils into suppressive cells with higher expression of ROS and ARG1 having 
immunosuppressive activity 369. 
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Importantly, neutrophils can mediate the activation of immune checkpoints on T cells. It has been 
shown that, within hepatocellular carcinoma (HCC) and gastric cancer, cancer-mediated activation 
of STAT3 pathways in neutrophils prolonged their survival and increased expression of PD-L1 on 
their surface impairing T cell function through the PD-1/PD-L1 signaling pathway 370 371 372. Beside 
PD-L1, other immune checkpoint regulators, including VISTA, are expressed on neutrophils. 
However, the role of VISTA in neutrophils and its impact on tumor immunity require further 
investigation 373. Of note, in a model of melanoma, Fas-ligand expressed on TANs was able to induce 
cell apoptosis of tumor infiltrating lymphocytes that mediated resistance to cancer immunotherapy 
374. 
Although the crosstalk between neutrophils and T cells is the most studied, it has been reported as 
well that neutrophils can orchestrate the functions of other components of the immune system, in 
an immunosuppressive direction. Indeed, neutrophils are able to prevent the NK cell-mediated 
clearance of tumor cells 375. In addition, it has been recently proven that neutrophils can promote 
metastasis by coating tumor cells with NETs, therefore preventing cytotoxic activity of CD8 T and 
NK cells 342. Moreover, through the release of chemokines such as CCL2 and CCL17, neutrophils are 
able to recruit monocytes and T regulatory cells with pro-tumoral behavior at the tumor site 247. In 
addition, evidence showed that MPO-driven lipids peroxidation and their accumulation in 
neutrophils impaired cross-presentation by DCs and pharmacological inhibition of MPO in 
combination with checkpoint blockade reduced tumor progression in different tumor models 376. 
Finally, in ovarian cancer patients, tumor associated ascites prolonged neutrophils lifespan and 
induced ROS secretion that may inhibit T cell proliferation 377. 
In conclusion, many evidence described neutrophils as an immunosuppressive and pro-tumorigenic 
subset. Some of the conclusions from these studies, however, require caution as the function of 
neutrophils was often determined in vitro using circulating or splenic neutrophils that do not 
correspond to tissue neutrophils, or in vivo, upon antibody-mediated depletion with the limitation 
inherent with this approach (Tab. 1). Therefore, consequent findings are challenging to interprets 




Table 1. Published work of T cell-suppressive behavior of neutrophils in tumors.  
 
1.12. TANs with anti-tumorigenic properties  
Even if most of the evidence showed that neutrophils are able to induce tumor progression, it has 
been proven that neutrophils can also mediate resistance against primary carcinogenesis in mouse 
and human. In fact, neutrophils are able to kill the cancer cells via 1) release of ROS, NO, TRAIL and 
TNF or 2) via contact-mediated mechanism or 3) by engaging in cooperative network with innate 
and adaptive lymphoid cells 378 379 57 380.  
Regarding the crosstalk with other cells of immune system that promote anti-tumor response, it has 
been shown that neutrophils can release DC-maturing cytokines, such as TNF-, or induce the 
maturation of mo-DCs by cell-cell contact-dependent mechanisms contributing to the launching of 
the adaptive immune response 381 382. Moreover, neutrophils deficiency was associated to a 
selective impairment of type I polarization and IFN- production in a subset of unconventional CD4-
CD8 T cells 383. Also, in colorectal cancer, co-localization of neutrophils and CD8 T cells was 
associated with a better prognostic value 384.  
Importantly, chemokines including CXCL10, CCL2, CCL3, CCL5, CXCL1 and CXCL2 released by 
neutrophils in the TME are able to recruit many immune subsets such as T cells and DCs, supporting 
anti-tumor immune responses 385 383 386 381. Surprisingly, in early stage of lung cancer, a subset of 
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activated tumor infiltrated neutrophils (TANs) named “APC-like hybrid TANs” has been identified. 
This subset is characterized by an atypical expression of surface markers which belong to the 
professional APCs (CD86, CD14, HLA-DR, CCR7), which are able to amplify the anti-tumor T cell 
response and are absent in more advanced tumors 387 382.  
Collectively, current data suggest that the significance of neutrophils and their functions in the 
circulation and in the neoplastic setting requires deeper clarification and may be strongly influenced 
by the tissue and the tumor context. Moreover, relate the complex plasticity of neutrophils to a 
specific microenvironment as well as patient prognosis and response to therapy represent an 
important challenge in the field. Lastly, there is no consensus nomenclature for the emerging 
complexity of neutrophils differentiation and activation states, and an unequivocal strategy to 
detect immunosuppressive neutrophils and other neutrophil subsets remains to be developed. 
 
1.13. SiglecFhigh neutrophil as tumor-promoting subset in lung cancer 
TANs represent an important component of the niche of many murine and human tumors and 
understanding their complex diversity and plasticity in tissue specific tumor microenvironment will 
provide the basis to develop new therapeutic approaches. Usually, the presence of neutrophils in 
human tumors is assessed by immunohistochemistry and only recently a transcriptional signature 
based-identification has been introduced 272. In particular, transcriptomic analysis and 
deconvolution of immune subsets in NSCLC showed a dominance of TAN that  negatively correlates 
with T cell infiltration 388. So far, a set of surface markers can be used to unequivocally identifies 
neutrophils which include CD11b/CD66b in human and CD11b/Ly6G in mice. However, the existing 
nomenclature (Fig. 1.5) is not sufficient to discriminate differently polarized subsets of neutrophils 
in tumor tissues and a more robust system to define this complex population is needed.   
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Figure 1.5. Nomenclature for neutrophil diversity in cancer. Set of surface molecules that identifies different subsets of neutrophils in 
human and mice. Additional molecules have been proposed to identify neutrophils in tumor contests which include PD-L1, LOX1, CD84 
associated with tumor progression and CD101 and CD177 associated with tumor regression 302.   
In a recent work, R. Zilionis and colleagues, through a scRNA-seq analysis of immune population in 
NSCLC as well as in a transplantable orthotopic lung cancer model, were able to identify five subsets 
of neutrophils (hN1-hN5) in human and six in mice (mN1-mN6) with conserved aspects between the 
two species. They identified three conserved modules of neutrophil gene expression within mouse 
and human: 1) neutrophils that express canonical markers (hN1 and mN1), 2) tumor specific subsets 
that promote tumor growth in mice (hN5 and mN5) and 3) a subset characterized by the expression 
signature of type I interferon response (hN2 and mN2). In addition, the authors observed that the 
over-expression of subsets-specific genes in patients associated with the overall survival, opening 
an opportunity to expand the number of tumor-associated markers used to identify neutrophils. As 
an example, the hN5 marker phosphoinositide 3-kinase (PI3) negatively correlated with patient 
survival 253.  
Importantly, in a previous work, C. Engblom and colleagues, were able to identify by flow cytometry 
two subsets of neutrophil in lung of mice which can be distinguished according to the expression 
levels of the sialic acid binding lg-like lectin F (SiglecF). They demonstrated that an increased bone-
stromal activity in autochthonous lung adenocarcinoma model was able to affect distant tumor 
progression and Ocn+ cells were required for tumor infiltration by a SiglecFhigh neutrophils. Those 
neutrophils preferentially accumulate in murine lung cancer, while the SiglecFlow subset appeared 
in high numbers already in healthy lungs 389. Interestingly, single cell transcriptomic data revealed 
that SiglecFhigh neutrophils express gene associated with angiogenesis, extracellular matrix 
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remodeling and T cells suppression and correspond to mN4 and mN6 subsets that were indeed 
highly enriched in tumor. In contrast, SiglecFlow neutrophils (corresponding to mN1 to mN3 subsets) 
already exist in healthy tissue and were not associated to tumor growth 253 389 390. Siglecs molecules 
are well characterized lectins important for tolerance induction, pathogen recognition and uptake, 
and regulation of cells activation. In particular, the SiglecF component was first associated with a 
suppressive role on eosinophils, but its function on other cells remains unclear 391. 
In 2020, C. Pfirschke and colleagues, better characterized the SiglecFhigh neutrophils populating 
transplantable murine lung adenocarcinoma defining those cells as bona-fide mature cells that 
differ from other myeloid cells expressing SiglecF (including eosinophils, macrophages and MDSCs). 
This population has not been found into the bone marrow, in the spleen and blood of lung-tumor 
bearing mice 392 but appeared in other districts such as heart and nasal mucosa during inflammation 
and tissue damage 393 394.  In addition, Pfirschke and colleagues demonstrated that neu-SiglecFhigh 
are characterized by an increased lifespan (up to several days compare to hours of SiglecFlow 
counterpart) and therefore gradually accumulate in growing lung tumors 392. Moreover, in 2021 P-
B. Ancey and colleagues, demonstrated that in autochthonous model of lung cancer, neu-SiglecFhigh 
undergo metabolic changes exhibiting several pro-tumor functions. They identified GLUT1 as key 
regulator of enhanced glucose metabolism and neutrophil survival which in turn promoted 
neutrophil tumor supportive behavior. In addition, loss of GLUT1 accelerated neutrophils turnover 
and reduced the presence of neu-SiglecFhigh in tumors leading to decrease of tumor growth and 
better responses  to radiotherapy 295. 
Thus, neutrophils are an essential part of the lung cancer microenvironment and those expressing 
SiglecF may represent a target for new therapeutic approaches. Generally, to decipher whether 
neutrophils are involved or not in pathological events, anti-neutrophils antibodies (that target 
surface markers such as Ly6G or Gr1 which are not able to discriminate different subsets of 
neutrophils) are widely used to deplete these cells in vivo. However, the available antibodies suffer 
some limitations and are partially effective because of continuous recruitment from the bone 
marrow 395. 
Because of the lack of a valid approach to interfere with neu-SiglecFhigh recruitment in vivo, 
understanding how this population interact with different subsets in the TME and how influence 
the microenvironment of lung cancer remain to be elucidated. In addition, even if present evidence 
suggests that tumor derived circulating factors  (such as sRAGE) could promote the activation of 
bone marrow-resident cells that support accumulation of cancer-promoting neu-SiglecFhigh at the 
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tumor site 389, the origin of this class of neutrophils and the mechanism of their recruitment in lung 
cancer remain elusive. Moreover, the crosstalk with lung tissue specific anti-cancer T cell responses 
has not been investigated. In conclusion, neutrophils expressing SiglecF are a subset of neutrophils 
populating tumor bearing lungs which exhibit pro-tumorigenic behavior in vivo. A better 
characterization of this population may open possibilities for development of new specific 
therapeutic approaches for lung cancer without affecting other neutrophil subsets that are essential 




























2. Aim  
 
Neutrophils have emerged as a key immune suppressive population in lung cancer. Their diversity 
and complexity in lung cancer tissue have become apparent with the identification of one specific 
subset of long-lived neu-SiglecFhigh being preferentially enriched in adenocarcinoma. Evidence 
shown that the accumulation of neutrophils expressing SiglecF in lung cancer is mediated by the 
activation of bone marrow-resident cells and this subset expressed gene associated to tumor 
progression. However, the tumor secreted factors that determine their accumulation in lung cancer 
tissues are still elusive as well as their impact on endogenous anti-cancer T cell responses. 
The goal of this thesis was first to identify cancer derived factors involved in recruitment and 
accumulation of neu-SiglecFhigh in lung tumors. Upon identification of the chemokine CXCL5 as the 
major pathway, the next objectives have been 1) to interfere with expression of the chemokine by 
KP cancer cells, which was achieved by Crispr/Cas9 genome editing approach and 2) to analyze the 
implication of CXCL5 depletion in lung cancer microenvironment by multiparametric analysis by flow 
cytometry used to assess the accumulation of neutrophils and other immune cell subsets in CXCL5-
null KP tumors. Last, having established the system I have evaluated the impact of neu-SiglecFhigh on 















3. Materials and methods  
3.1. Mice and in vivo treatment 
C57BL/6 mice were purchased from Envigo Laboratories, whereas the OT-I (C57BL/6-
Tg(TcraTcrb)1100Mjb/J) strain was purchased from Jackson Laboratories. Animals were maintained 
in sterile isolators at the ICGEB animal Bio-experimentation facility. Ethical and experimental 
procedures were reviewed and approved by the Italian Ministry of Health (approval number 
1133/2020-PR, issued on 12/11/2020). 
To establish the adenocarcinoma tumor models C57BL/6 WT mice at 8-10wks of age, were 
intravenously injected with 7x104 non immunogenic KP cells or with 2x105 immunogenic variants 
(KP OVA, WT or KOCXCL5, KOCXCL5 (lenti-CXCL5) or KOCXCL5 (lenti-Vec)). Tumor bearing mice were sacrificed at 
initial (9 days upon tumor induction) or at more advanced stage of tumorigenesis (18 days upon 
induction), otherwise indicated, to perform downstream analysis.  
In some experiments, mice challenged with KP OVA cells were treated every 3 days, starting from 
the 6th day to 12th day, with anti-Ly6G (InVivo Plus, clone 1A8, BioXcell) antibody or isotype control 
(Rat IgG2a isotype control, clone 2A3, BioXcell) at the concentration of 200µg/100µL 
intraperitoneally to induce in vivo neutrophils depletion. For these experiments, mice were 
sacrificed at day 13th. 
In one experiment, mice were challenged with KP OVA WT or KOCXCL5 cells and treated starting from 
the 3rd day to 12th day, every 3 days, with antibody to PD-L1 (InVivoMab, clone 10F.9G2, BioXcell) 
or isotype control (InVivoMab, rat IgG2b isotype control, clone LTF-2, BioXcell) at the concentration 
of 200µg/100µL intraperitoneally to assess sensibility to immune checkpoint blockade therapy. In 
this setting, mice were sacrificed at day 18th.  
For adoptive transfer of tumor specific T cells, CD8 T cells were isolated from single cell suspension 
from lymph nodes of OT-I mice at 8-10 wks of age using CD8a+ T cell isolation Kit (Miltenyi) following 
the manufacturer’s instructions. The isolated OTI-CD8+ T cells were labelled with CFSE 
(thermoFisher) and 2x106 OTI+CFSE+ T cells were intravenously injected into mice carrying WT or 
KOCXCL5 tumors induced 9 days before. Mice were sacrificed 2 days after adoptive transfer to assess 
proliferation and IFN- production in OTI T cells.  
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3.2. Cell lines 
Transplantable KP cell line (KP1233) has been generated from lung tumors of C57BL/6 KP mice (K-
rasLSLG12D/+;p53fl/fl mice) and was kindly provided by Dr. Tyler Jacks (Massachusetts Institute of 
Technology, Cambridge, USA) in July 2015.  
To obtain an immunogenic cell line (KP OVA), KP cells were transduced with a lentivirus carrying the 
expression vector Pdual-liOVAha-PuroR, encoding ovalbumin (OVA) protein (kindly provided by 
David Murrugarren, CIB, Navarra). After 2 days of antibiotic selection with puromycin, cells were 
subcloned and single cell clones were tested for HA-OVA expression by intracellular staining by flow 
cytometry. One clone with intermediate OVA expression was selected as KP OVA cell line. 
To generate KOCXCL5 a specific guide for CXCL5 gene (for 5’-caccgCTGCCGCAGCATCTAGCTGA-3’ rev 
5’-aaacTCAGCTAGATGCTGCGGCAGc-3’) was designed using the online tool “Broad Institute web 
portal” to minimize potential off-target effects. The pZac2.1-U6sgRNA-CMV-ZsGreen plasmid was 
digested with bbsI restriction enzymes to allow cloning of the guide under the control of U6 
promoter. This plasmid was transiently transfected, together with a second plasmid (pSpCas9(BB)-
(PX458)) coding for Cas9 protein, in KP OVA cells by lipofectamine 3000 (Invitrogen) following 
manufacturer’s instructions. 24hrs after the transfection, the ZsGreen+ cells were purified using 
FACS cell sorting (FACS Aria II BD bioscience) and subcloned. Single clones were tested for CXCL5 
expression by qRT-PCR and by ELISA kit (abcam). Plasmids were kindly provided by dr. Mauro Giacca, 
ICGEB, Trieste. 
To generate KOCXCL5 (lenti-CXCL5) cells, KOCXCL5 cells were transduced with a lentivirus carrying the 
expression vector pLVX-IRES-G418-CXCL5, encoding CXCL5. As control, KOCXCL5 cells were also 
transduced with lentivirus carrying empty pLVX-IRES-G418 vector. After 2 days of antibiotic 
selection with G418, cells were tested for CXCL5 production by qRT-PCR and ELISA kit (abcam). 
All cell lines were maintained in DMEM media (containing 1g/L of glucose) supplemented with 10% 
fetal bovine serum (FBS, Euroclone) and Gentamicin (50μg/mL, Gibco) and routinely tested for 
mycoplasma contamination. Cells were expanded to passage 3 and stored in aliquots in liquid 
nitrogen. For tumor induction, cells were cultured less than five passages. 
 
3.3. Lentivirus production and cell infection 
The expression plasmid and relative packaging with envelope (Table 2) were co-transfected into 
HEK293T cells using Lipofectamine 3000 (Invitrogen) following manufacturer’s instructions. Forty-
eight hours after transfection, the supernatant containing virus particles was collected and filtered 
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with a 0,45m filter (millex-HV). Concomitantly, 9×106 KP or KOCXCL5 cells were plated in a 6-well 
plate (Falcon). Once attached, supernatant containing the virus was added to the cells which were 
subsequently infected through spinoculation at 800g for 60 min in the presence of polybrene 
(6g/mL, Invitrogen). The day after, the virus was removed and supernatant replaced with 2mL of 
fresh medium supplemented with the respective antibiotic to select the transduced cells. 
Lentiviral 
expression 





sPAX2 p-CMV-VSV-G Ampicillin G418 
Pdual-lOVAha sPAX2 p-CMV-VSV-G Ampicillin Puromycin  
Table 2. Summary of lentivirus plasmid.  
In order to produce the lentiviral expression pLVX-IRES-G418-CXCL5 plasmid, the pLVX-IRES-G418 
vector (kindly provided by dr. Serena Zacchigna, ICGEB, Trieste) was digested with NotI and XhoI 
restriction enzymes to allow the insertion of the coding sequence (CD) of Cxcl5 
(https://www.ncbi.nlm.nih.gov/nuccore/NM_009141.3) under the control of CMV promoter. The 
CD of Cxcl5 was isolated from pGi-CXCL5 plasmid through NotI and XhoI restriction enzyme-
mediated excision and DNA isolation from agarose gel by GFX PCR DNA AND GEL BAND purification 
kit (GE Healthcare) following manufacturer’s instructions. The AAV plasmid pGi-CXCL5, containing 
the CD of Cxcl5 was kindly provided by dr. Mauro Giacca, ICGEB, Trieste. 
 
3.4. In vitro cell line growth rate 
To determine the growth rate of cells in vitro, 3x103 cells were cultured in a flat p96-well (Falcon) 
and fixed at different time points (day 1, day 2 and day 3 of culture) in 1%PFA for 2 hrs. Cells were 
washed with PBS and stained with crystal violet dye following manufacturer’s instructions to assess 
cells viability. Upon dye solubilization by 1%SDS the OD at 595nm, proportional to vital and 
proliferated cells, was measured by microplate reader (iMark, Biorad).  
 
3.5. Tissue preparation and cell isolation 
Normal or tumor-bearing lungs were harvested after PBS lung circulatory perfusion, mechanically 
cut into small pieces and digested with 0,1 % Collagenase type 2 (265U/mL; Worthington) and 
DNase I (250U/mL; Thermo scientific) at 37°C for 30’. Collagenase was stopped by EDTA 10mM and 
the cell suspension was filtered using 70μm cell strainer (Corning). Blood cells in the suspension 
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were lysate by ACK (Gibco) solution. The obtained single cell suspension was stained for flow 
cytometry analysis. 
In one experiment, single cell suspension obtained from healthy or tumor bearing lungs was stained 
with CD45-A647 (30-F11, Biolegend) antibody and CD45+ or – populations were sorted by FACS Aria 
II (BD Biosciences) for qRT-PCR analysis.  
Other tissues were collected from healthy or tumor bearing mice including blood (collected through 
subclavian vein puncture), spleen, lymph nodes (mediastinal and inguinal) and bone marrow. To 
avoid coagulation, EDTA (0,5M, Gibco) was added to blood samples. Single cell suspension from 
spleen and lymph nodes was obtained through filtration with a 70 μm and 40 μm cell strainer 
respectively. Bone marrow single cell suspension was obtained through flushing with 0,5mL-26G 
syringe (Terumo) from leg bones (femur and tibia). Therefore, red cells were lysate in all samples by 
ACK solution and the obtained single cell suspension was stained for flow cytometry analysis.  
 
3.6. Flow cytometry 
Antibodies used are listed in table 3. Viability of cells was assessed by staining with LIVE/DEAD 
Fixable Aqua Dead Cell Stain Kit (Life Technologies). FcR binding sites were blocked by using 
αCD16/CD32. Myeloid cell subsets were identified as showed in Figure 4.2a by multiparametric-
based analysis which include classification based on physical parameters (SSC-A and FSC-H), dead 
cell and doublets exclusion, and expression of extracellular markers as following: cDCs 
(CD45+CD11c+MHCIIhiSiglecF-), AM (CD45+CD11b-CD11c+SiglecF+), TAM (CD45+SiglecF-Ly6C-Ly6G-
MHCII+CD64+), neu (CD45+CD11b+Ly6G+), neu-SiglecFhigh (CD45+CD11b+Ly6G+SiglecF+), neu-
SiglecFlow (CD45+CD11b+Ly6G+SiglecF-), neu-SiglecFhigh or low expressing CXCR2 (CXCR2+), neu-
SiglecFhigh or low expressing PD-L1 (PD-L1+), eosinophils (CD45+CD11b+SiglecF+Ly6G-), monocytes 
(CD45+CD11b+Ly6C+Ly6G-), NK cells (CD45+CD19-CD3-B220-NK1.1+), B cells (CD45+CD3-CD19+B220+), 
CD4+ T cells (CD45+CD3+CD4+), CD8+ T cells (CD45+CD3+CD8+), activated T cells (PD1+LAG3+TIM3+), 
memory T cells (CD62l-CD44+). Where indicated, absolute cell count was analyzed by adding 
TrueCount Beads (Biolegend) to the samples following manufacturer’s instructions.  
To identify OVA specific CD8 T cells (CD45+CD3+CD8+pentamers+) lung cell suspensions were stained 
with MHC-I-OVA pentamers tool (SIINFEKL/H-2Kb Pro5, Proimmune) following manufacturer’s 
instruction.  
For intracellular detection of IFN, single cell suspensions from lung or mLN were stimulated with 
OVA peptide (SIINFEKL) 2µM 37°C for 4 hrs in the presence of Golgi Stop (monensin, BD Biosciences) 
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to allow accumulation of cytokines within Golgi apparatus. Upon extracellular staining, cells were 
fixed and permeabilized using Cytofix/Cytoperm solution (BD Biosciences) following manufacturer’s 
instructions, and then stained with IFN-PE antibody.  
To identify effector EOMES-Tbet+ CD8+ T cells, upon extracellular staining labelling CD45+CD3+CD8+ 
T cells, single cell suspensions from lung and mLN were fixed and permeabilized using 
Foxp3/transcription factor staining buffer set (ThermoFisher) following manufacturer’s instructions 
and stained with anti-mouse EOMES and anti-mouse T-bet antibodies. 
To measure OVA expression, different cell lines were fixed and permeabilized using 
Cytofix/Cytoperm solution (BD Biosciences) following manufacturer’s instructions, stained with rat-
antibody against HA bonded to OVA protein and with RAT-IgG-AF488 (Invitrogen). Samples were 
acquired with FACS Celesta (BD Biosciences) and analyzed with FlowJo software (Tree Star, Inc.). 
 
Antibody Fluorophore Clone Brand 
CD45 APCCy7 30-F11 Biolegend 
CD3 PerCPCy5.5 145-2C11 Biolegend 
CD3 FITC 145-2C11 Biolegend 
CD4 BV785 GK1.5 Biolegend 
CD8 APC 53-6.7 Biolegend 
CD62l BV650 MEL-14 Biolegend 
CD44 PE IM7 Biolegend 
PD-1 EF450 J43 eBioscience 
TIM3 PerCPCy5.5 RMT3-23 Biolegend 
LAG3 BV650 C9B7W Biolegend 
IFN- PE MG1.2 Biolegend 
EOMES A647 W17001A Biolegend 
Tbet BV421 4B10 Biolegend 
SIINFEKL/H-2Kb Pro5 PE  ProImmune 
CD11b BV421 M1/70 BD Bioscience 
SiglecF PerCPEF710 IRNM44N eBioscience 
SiglecF BB515 E50-2440 BD Bioscience 
CD11c BV786 N418 Biolegend 
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CD11c APC N418 Biolegend 
MHC-II APCR700 M5/114.15.2 Biolegend 
CD86 PE B7-2 BD Bioscience 
PD-L1 PerCPeF710 MIH5 eBioscience 
CD64 BV605 X54-5/7.1 Biolegend 
Ly6C AF488 HK1.4 eBioscience 
Ly6C BV570 HK1.4 Biolegend 
Ly6G AF488 1A8 Biolegend 
Ly6G PE 1A8 Biolegend 
CXCR2 PerCPCy5.5 SA044G4 Biolegend 
B220 APC C363-16A Biolegend 
CD19 PE 1D3 BD Bioscience 
NK1.1 Biotin PK136 Biolegend 
Streptavidin PE-Cy7  Biolegend 
L&D BV510  Life Technologies 
CD16/CD32  93 Biolegend 
HA  3F10 Roche 
Table 3. list of used antibodies 
 
3.7. Real time PCR 
Normal or tumor bearing lung were mechanically dissociated and RNA was extracted from 
dissociated normal or tumor bearing lung tissues or cells by using Trizol reagent (ThermoFisher 
Scientific), according to manufacturer’s instruction. cDNA was synthesized using SuperscriptII 
(ThermoFisher) and real-time PCR for gene expression was performed using SsoFast EvaGreen 
Supermix (Biorad) with specific primers: Gapdh For (AGAAGGTGGTGAAGCAGGCAT) Rev 
(CGAAGGTGGAAGAGTGGGAGT), Cxcl5 For (GCT GCC CCT TCC TCA GTC AT) Rev (CAC CGT AGG GCA 
CTG TGG AC). 
Thermal cycle conditions were the following: 95°C for 3 minutes, 43 cycles of 95°C for 10 seconds, 
and 60°C for 30 seconds. Each sample was analyzed in triplicates. Cxcl5 expression in cell lines was 
obtained by normalizing target genes to Gapdh used as reference gene (ΔC(t)). Expression 
corresponding to 2ΔC(t) (2C(tCxcl5)-C(tGapdh), where CT is the signal of the PCR product which exceeds the 
background signal) was showed. CXCL5 expression in tissues was obtain by normalizing the ΔC(t) of 
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tumor bearing lung to ΔC(t) of normal lung (ΔΔC(t)). The relative abundance corresponding to 2ΔΔC(t) 
was showed.  
In one experiment, gene expression profiling of inflammatory cytokines and receptors of normal 
and KP-OVA tumor bearing lungs was performed by custom RT2 Profiler PCR Array (Qiagen, cat. 
330221) following manufacturer’s instructions. 
 
3.8. CXCL5 detection by ELISA 
3x106 cells/200uL were incubated at steady state with medium 5 hrs and CXCL5 production in the 




To assess tumor burden, lung tissues were harvested previous PBS lung circulatory perfusion, fixed 
in formaldehyde 10% and paraffine embedded following standard procedure. Consecutive sections 
of 8m were dewaxed and rehydrated and stained with the H&E using (Bio-Optica, Milano Spa). 
Limonene was used as mounting media. The area of tumor nodules was quantified manually over 
consecutive sections and averaged (3 sections/sample). The area occupied by tumor nodules was 
expressed as a function of the total lung lobe area. Automatic thresholding and measurements were 
performed using Ilastik or imageJ software, respectively.  
To identify CD8+ T cells or neutrophils infiltrating lung tumors or proliferating cells within nodules, 
sections of paraffine embedded lung tissue were dewaxed and rehydrated and treated with antigen-
retrieval solution (Vector laboratories) for 20 min at 120°C. Slides were treated for 10 minutes in 
H2O2 to block endogenous alkaline phosphatase. After blocking in 10% goat serum in 0.1% Tween20 
for 30 minutes, slides were incubated overnight at 4°C in a humidified chamber with specific 
antibody diluted in PBS 0,1%Tween20: anti-mouse CD8 (4SM15, Invitrogen cat 14-0808-82), or anti-
mouse Ly6G (1A8, BD Pharmingen, cat 551459), or anti-mouse Ki67 (D3B5, Cell Signaling, cat 
12202s). Detection was performed using the ImmPRESS polymer detection system (Vector 
Laboratories), according to manufacturer’s Instructions. Slices were therefore stained with the 
hematoxylin to manually identify the tumor area (for proliferating cells eosin staining was 
performed instead). Limonene (Electron Microscopy Science) was used as mounting medium. 
Automatic thresholding and measurements were performed using Ilastik or imageJ software, 
respectively. Images were acquired by Leica microscope using 10x, 20x or 40x objectives. 
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3.10. Immunofluorescence staining 
To identify neu-SiglecFhigh cells within nodules of KP OVA tumors, lungs tissues were harvested 
previous lung perfusion via trachea with 1% paraformaldehyde (PFA), fixed in 4% PFA and 
embedded in a frozen tissue matrix following standard procedure. Sections of 5m were dried 15’ 
at room temperature (RT) and permeabilized for 15’ in 0,5% Triton. After blocking in 5% mouse 
serum in 1%BSA/0,1%NP-40 for 30’, slides were incubated overnight at 4°C in a humidified chamber 
with specific fluorophore-conjugated antibody diluted in PBS 1%BSA/0,1%NP-40: anti-mouse Ly6G-
PE and anti-mouse SiglecF-BB515 (listed in table 3). Nucleus were labelled by Hoechst and Mowiol 
4-88 (Sigma) was used as mounting medium. Images were acquired with LSM880 META reverse 
microscope with a 40x objective. 
To assess spatial distribution of neutrophils and CD8 T cells lung tissues bearing KP OVA tumors were 
harvested previous PBS lung circulatory perfusion, fixed in formaldehyde 10% and paraffine 
embedded following standard procedure. Consecutive sections of 8m were dewaxed and 
rehydrated and treated with antigen-retrieval solution (Vector laboratories) for 20 min at 120°C. 
After blocking in 10% goat serum in 0.1% Tween20 for 30 minutes, slides were incubated overnight 
at 4°C in a humidified chamber with rat anti-mouse CD8 (4SM15, Invitrogen) and rabbit anti-mouse 
Ly6G (E6Z1T, Cell Signaling) antibodies diluted in PBS 0,1%Tween20 followed by specific secondary 
antibodies. Nucleus were finally labelled by Hoechst and Mowiol 4-88 was used as mounting 
medium.  
Images were acquired with C1 Nikon reverse microscope with a 20x objective. Automatic 
thresholding was performed by Ilastik. ImageJ software was used to quantify CD8 T cells and neu 
and to measure nodule’s area. Nodules having an area <0,09 mm2 were classified as small, the ones 




Primary data were collected in Microsoft Excel and statistical analysis were performed by using 
Graphpad Prism 8 software. Values reported in figures are expressed as the standard error of the 
mean, unless otherwise indicated. For comparison between two or more groups with normally 
distributed datasets 2-tailed Student’s T test, multiple T test, one-way ANOVA or 2-way ANOVA 
were used as appropriate. For the comparison of matched groups, we used Wilcoxon test. The non-
parametric Kruskal-Wallis test with Dunn’s multiple comparison was performed to compare 3 or 
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more unmatched groups. p values > 0.05 were considered not significant, p values  0.05 were 































4.1. Orthotopic KP tumors are dominated by SiglecF high neutrophils 
To study the role of neutrophils in lung tissue during progression of primary lung tumors, we 
established a transplantable model of lung adenocarcinoma using a cell line derived from primary 
KP tumors (KrasG12D/+; Trp53-/-) 396 that gives rise to lesions similar to human non-small cell lung 
adenocarcinoma in terms of genetic mutations and histopathological features 397. We generated an 
OVA expressing variant of the original line by lentiviral transduction of the model antigen ovalbumin 
(OVA-HA) to allow tracking of T cell responses against a defined tumor antigen in an immunogenic 
model. The transduced cells were selected under puromycin resistance and subsequently subcloned 
(Fig. 4.1a). Single clones were therefore tested for OVA expression by intracellular staining by flow 
cytometry using an antibody against the hemagglutinin (HA) tag. We tested different clones and we 
selected, a clone (A4) which showed an intermediate expression of OVA. This selected clone is 
referred to KP-OVA cell line hereafter and it was used to induce immunogenic lung tumor lesions in 
vivo (Fig.4.1b-c).  
 
Figure 4.1 Generation of KP-OVA cell line. A) KP cell line was transduced with OVA-expressing lentivirus. The transduced cell line was 
selected under puromycin resistance and sub-cloned. B) Single clones were analyzed for OVA expression by intracellular flow cytometry 
staining and mean fluorescence intensity (MFI) of OVA was plotted nearby each corresponding histogram. C) The “A4” clone were 




KP and KP-OVA tumors were intravenously induced and lung tissues were harvested when nodules 
were clearly visible (15-20 days after challenge). To phenotype the immune infiltrate of KP lung 
tumors we set up a multiparametric-based gating strategy to identify several immune subsets 
(neutrophils, NK cells, eosinophils, alveolar macrophages, B cells, T cells and DCs) as illustrated in 
Fig.4.2a. In particular we noted that the KP model is characterized of an abundant myeloid 
infiltration dominated by Ly6G+ CD11b+ neutrophils (neu). The immune landscape of KP-OVA tumors 
is similar to KP tumors and is characterized by an even higher infiltration of neu. In both models we 
observed a slight decrease in B cells and CD4 T cells compare to normal lung (nLung) and as 
expected, an increment in CD8 T cells in the immunogenic KP-OVA model (Fig.4.2b).  
 
Figure 4.2 Immune infiltrate of KP or KP-OVA tumors. A) Gating strategy used to identify by flow cytometry different myeloid 
populations in normal lungs and established KP or KP-OVA tumors. B) mice were challenged with KP and KP-OVA cells and 20 days 
after induction normal and tumor bearing lungs were harvested to analyze the immune landscape by flow cytometry. Quantification 
of relative abundance of each subset expressed as a fraction of CD45+ cells. Data are mean±SEM of 3-4 mice each group.  
To further phenotype tumor infiltrating neu, we analyzed by flow cytometry the expression of the 
marker SiglecF which was recently shown to identify a population of long-lived mature neu in lung 
 51 
tumors 392. In line with recent evidence 389 392 we found that up to 70% of neu in KP tumors expressed 
the lectin SiglecF (neu-SiglecFhigh), whereas neu in normal lung showed low SiglecF expression (neu-
SiglecFlow). Of note, Neu-SiglecFhigh were present in similar proportion in immunogenic KP-OVA 
tumors, demonstrating that their accumulation occurs also in the presence of an ongoing response 
against tumor antigens (Fig.4.3).  
 
Figure 4.3 Representative dot plot and quantification of relative abundance of SiglecF high/low neutrophils expressed as a fraction of 
CD45+ cells. Mice were inoculated with KP or KP-OVA cells and neutrophils subsets were analysed after 18 days by flow cytometry in 
normal or tumor bearing lungs. Frequencies represent the mean±SEM of three mice each group. Also, frequencies of SiglecF high/low 
neutrophils expressed on total CD11b+Ly6G+ were showed as % in the graph.  
Having confirmed the presence of neu-SiglecFhigh in immunogenic tumors we performed the 
remaining experiments using the KP-OVA model.  
We next asked whether neu-SiglecFhigh are present systemically or in lymphoid organ of tumor 
challenged mice. To this aim we analyzed the spleen, the bone marrow (BM), the mediastinal lymph 
node (mLN) draining the lung, other lymph nodes (such as the inguinal LN) and the blood of KP OVA 
tumor bearing mice by flow cytometry. 
 
Figure 4.4 Expression of the lectin SiglecF on systemic or lymphoid-derived neutrophils. Tumors were induced with KP-OVA cell line 
and 15 days after challenge the expression of SiglecF on neutrophils from lung, BM, blood, spleen, and lymph nodes (lung draining 
mLN and inguinal LNs) of tumor bearing mice were analyzed by flow cytometry. Quantification of relative abundance of neutrophils 
SiglecFhigh or low expressed on total CD11b+Ly6G+ was showed in the graph. Data represents the mean±SEM of 4 mice each group. 
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According to previous data, neu-SiglecFhigh represented the 70% of total neutrophils in lungs. Of 
note, we were able to detect the SiglecF expressing subset also in mLN where represented the 20% 
of total CD11b+Ly6G+ cells. However, those cells were absent in all the other tested compartments 
(Fig.4.4), indicating that neu-SiglecFhigh populated specifically lung tumor tissues and connected 
lymph nodes. 
To visualize the distribution of neu within lung tumor tissues we performed IHC and tissue immune 
fluorescence (IF). Labeling with Ly6G antibody of paraffine embedded KP OVA tumor bearing lung 
showed that the accumulation of neu in lung tumors occurred only inside the nodule (Fig.4.5a). In 
addition, by labelling of cryo-tissues with both SiglecF and Ly6G antibodies we confirmed by IF the 
presence of neu-SiglecF+ infiltrating nodules of KP OVA tumors (Fig.4.5b). 
 
Figure 4.5 Neu accumulate in nodules of KP-OVA tumors. Mice were challenged with KP OVA cells and after 9 days tumor bearing 
lungs were analyzed by IHC and IF. A) Representative 10x section of paraffine embedded KP OVA tumor bearing lung labelled with 
Ly6G antibody identifying neutrophils (brown dots) and haematoxylin used to identify the tumor area (left). On the right the 40x 
magnification of a nodule was showed. B) the upper sections are representative IF analysis of a nodule of cryo-lung tumor tissues 
labelled with Ly6G (green) and SiglecF (red). The lower parts are a 60x magnification of a nodule. In the images on the right DAPI 
(blue), used to identify the tumor area within the tissues, was also showed.  
 
4.2. CXCL5 is highly expressed in KP tumors  
To explore the mechanism controlling accumulation of neu-SiglecFhigh in lung tumors, we profiled 
normal and tumor lung tissues using a gene array of chemokines and their receptors. As shown in 
Fig.4.6a, tumor tissue displayed 20-fold more Cxcl5 and 10-fold more Cxcl9 than normal tissues, 
besides a slight induction of other chemokines implicated in monocytes or neu recruitment. Cxcl5 
over-expression was confirm also by RT-PCR in KP and KP-OVA tumor bearing lung (Fig.4.6b). 
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Figure 4.6 Cxcl5 is over-expressed in both KP and KP-OVA tumors. A) mice were challenged with KP-OVA cells and after 20 days normal 
and tumor bearing lungs were harvested to analyze transcriptional profiles by Qiagen gene array. The graph shows differential 
chemokines and receptors gene expression in established KP-OVA tumors compared to nLung. B) Tumors were induced by KP or KP-
OVA cells in WT mice and 20 days after challenge Cxcl5 relative abundance was measured by real-time PCR in normal and tumor 
bearing lungs. Data represent the mean±SEM of 4-5 independent RNA extraction. Significance was determined by one-way anova 
with *p≤0.05, **p≤0.01. 
CXCL5 binding to its receptor CXCR2 has been previously associated with neu recruitment in 
inflammation and cancer 307 306 308 309. Therefore, we measured by flow cytometry the expression of 
CXCR2 on tumor infiltrating neutrophils and we observed that it was higher on neu-SiglecFhigh 
infiltrating KP-OVA tumors as compared to SiglecFlow counterpart (Fig.4.7). 
 
Figure 4.7 Neu-SiglecFhigh express high level of CXCR2 receptor. Mice were challenged with KP-OVA cells and after 18 days tumor 
bearing lungs were harvested and CXCR2 expression in neu-SiglecFhigh/low measured by flow cytometry. Representative histogram with 
corresponding median fluorescence intensity (MFI) of CXCR2 expression in neu-SiglecFhigh/low was showed. The relative quantification 
represents the mean±SEM of 4 mice. Significance was determined by t-test with ***p≤0.001. 
To identify the source of CXCL5 production in lung tumor tissues, we isolated by FACS cell sorting 
the myeloid (CD45+) and not-myeloid (CD45-) fractions from normal and tumor-bearing lungs and 
Cxcl5 expression in those fractions was assessed by qRT-PCR. The CD45- fraction isolated from tumor 
tissues, which include stromal and tumor cells, had the highest expression of the chemokine, 
suggesting that cancer cells themselves may be responsible for CXCL5 production in lung cancer 
(Fig.4.8a). Worth noticing, the KP OVA cell line in vitro at steady state, unlike others tumor cells (e.g., 
B16 melanoma and ID8 ovarian cell line), expressed higher amount of Cxcl5 compared to nLung 
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tissues. Importantly, Lewis lung carcinoma cells (LLC) did not express high amount of Cxcl5 at steady 
state, in line with previous reports documenting that elevated Cxcl5 expression is linked to Kras 
mutation 3 51, absent in these cells (Fig.4.8b). We conclude that increased Cxcl5 transcripts in KP 
lung tumor tissues is determined mostly by secretion of CXCL5 by KP tumor cells.  
 
Figure 4.8 CXCL5 is mainly produced by tumor cells. A) Mice were inoculated with KP cells and after 18 days CD45+ or – were isolated 
by cell sorting from normal or tumor bearing lungs and Cxcl5 expression in those fractions was analyzed by qRT-PCR. Data represent 
the relative expression of Cxcl5 on Gapdh. B) Cxcl5 expression was analyzed by qRT-PCR in different cell lines at steady state and in 
normal lungs. The relative expression of Cxcl5 on Gapdh was showed. Data represent the mean±SEM of 2-7 independent RNA 
extraction. Significance was determined by one-way anova with **p≤0.01.  
 
4.3. Ly6G antibody-mediated depletion of neu is poorly effective in lung tumors 
To explore the role of neu-SiglecFhigh in shaping anti-tumoral immune responses, we first tested the 
widely applied depletion strategy with antibodies to Ly6G, the specific marker of neu. Mice were 
challenged orthotopically with KP OVA cells and Ly6G antibodies were administered starting from 
the 6th day to the 12th day, every 3 days, to induce the in vivo complement-mediated elimination of 
neu. Mice were therefore sacrificed at day 13th to perform downstream analysis (Fig.4.9a) 
 
Figure 4.9 Scheme of in vivo antibody-mediated depletion of neu. Mice were challenged with KP-OVA cells and treated every 3 days, 
starting from the 6th day to 12th day, with 𝛼Ly6G or isotype to in vivo deplete neutrophils. Mice were sacrificed at day 13th and 
frequencies of neutrophils analysed in blood and lung tissues by flow cytometry. B) Frequencies of neutrophils CD11b+Ly6G+ expressed 
as % of total cells were analysed by flow cytometry in blood of challenged mice at days 7th and 13th. Data represent the mean±SEM 
of 3 mice/group. Significance was determined by 2-way anova with ***p≤0.001. 
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This approach efficiently depleted circulating neu that instead increased over time in blood of 
isotype-challenged mice (Fig.4.9b). We therefore analyzed by flow cytometry and IHC the presence 
of neutrophils in the lungs of challenged mice. In line with other evidence which shown the poorly 
effectiveness of antibody-mediated neutrophils depletion in tissues 395, frequencies of neu in 
Ly6G-tumor bearing lungs, analyzed by flow cytometry, slightly decreased as compared to isotype 
treated mice (Fig.4.10a). In addition, Ly6G labelling of paraffine embedded lung tumors revealed 
that neu (brown dots) still persisted within nodules upon Ly6G treatment (Fig.4.10b). 
 
Figure 4.10 Neutrophil-depletion is poorly effective in tumor bearing lungs. Mice were challenged with KP OVA cells and treated every 
3 days, starting from the 6th day to 12th day, with 𝛼Ly6G or isotype. Lungs were harvested at day 13th and frequencies of neutrophils 
analysed by flow cytometry and IHC. A) Representative dot plot and frequencies of neutrophils expressed as % of CD11b+Ly6G+ cells 
on CD45+ cells in isotype- or Ly6G-treated tumor bearing lungs. Frequencies represent the mean±SEM of 4 mice/group. B) paraffine 
embedded lung tumors were labelled with Ly6G identifying neutrophils (brown dots). Representative 10x section (left) and 40x 
magnification of nodule (right) were showed.  
Of note, in Ly6G-tumor bearing lungs, neutrophils showed a decreased expression of Ly6G as 
compared to isotype treated challenged mice. This may be due to the phenomenon of antigen 
masking, whereby an antibody used in vivo will prevent the binding of the same antibody if used to 
detect the target cells, resulting in low sensitivity and false negative measures. Moreover, evidence 
showed that neutrophils continuously recruited from bone marrow had lower Ly6G membrane 
expression that also reduced targets for anti-Ly6G antibody 395.   
Thus, we confirmed that the widely used approach of antibody-mediated depletion is not an 
effective way to deplete tumor infiltrating neutrophils in our model, stressing the need to search 
for a selective and specific way to target tumor infiltrating neu. 
 
4.4. Editing of KP OVA cells by Crispr/Cas9  
Based on findings presented in Figures 4.6-4.8, we next decided to delete the expression of CXCL5 
by Crispr/Cas9-based genome editing of KP-OVA cells to interfere with recruitment of the neu-
SiglecFhigh subset.  
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To this aim, by using the online tool “Broad Institute web portal”, we designed a sgRNA-guide 
specific for Cxcl5 gene that we cloned in a vector expressing the ZsGreen protein (sgCXCL5-ZsGreen 
vector). In order to avoid the constitutive expression of Cas9 protein which would arise from 
lentiviral transduction, this vector was transiently transfected, together with a second vector 
expressing the Cas9 protein (Cas9-vector), into KP OVA cell line. Therefore, after 24 hours the 
ZsGreen+ cells were isolated by FACS cell sorting and subcloned (Fig.4.11). 
 
Figure 4.11 Generation of deficient CXCL5 KP-OVA cell line. Scheme of the experimental procedure. KP-OVA cell line was transiently 
transfected with CAS9 and sgCXCL5-ZsGreen+ vectors. ZsGreen+ cells were sorted and subcloned to identify by ELISA WT or KOCXCL5 
clones. 
Upon subcloning of edited cells, we measured by ELISA the production of CXCL5 to identify both WT 
and KOCXCL5 clones. For the screening, edited cells were incubated in medium and the supernatant 
collected to test chemokine production by ELISA. We selected two clones with null expression of 
the chemokine and two clones that showed expression comparable to the original cell line 
(Fig.4.12a). Finally, we pooled the selected WT or KOCXCL5 clones in 1:1 ratio to reduce clone-related 
specific effects. Therefore, the resultant KP-OVA WT and KOCXCL5 cells were incubated in medium 
and the CXCL5 production in the supernatant validated by ELISA (Fig.4.12b). 
 
Figure 4.12 CXCL5 protein quantification. A) Single clones or B) the pooled WT or KOCXCL5 clones, were incubated 5 hrs at 37°C and 
CXCL5 production were measured in the supernatant by ELISA Data of panel A) represents the mean±SEM of 1 or 2 independent 
measurements. Data of panel B) represents the mean±SEM of 5 independent measurements. Significance was determined by a one-
way anova with ****p≤0.0001. 
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To control whether WT and KOCXCL5 cells maintained a similar OVA expression downstream the 
editing process, we performed an intracellular staining by flow cytometry using an antibody against 
the HA tag. FACS analysis showed a similar OVA expression in WT cells, expressed as median 
fluorescence intensity, as compared to KOCXCL5 (Fig.4.13a). Furthermore, we assessed the growth 
rate of the clones in vitro. To this goal, equal number of cells were cultured and fixed at different 
time points (at day 0, at day 1 and at day 2 of culture) and a crystal violet-based assay was used to 
quantify cell proliferation that was similar between WT and KOCXCL5 cells (Fig.4.13b).  
 
Figure 4.13 In vitro validation of WT or deficient CXCL5 KP-OVA cell line. A) Representative histogram of OVA expression measured by 
flow cytometry in KP-OVA WT or KOCXCL5 cells. The median of fluorescent intensity was plotted nearby the corresponding histogram. 
B) In-vitro growth rate of KP-OVA WT or KOCXCL5 cells. 3x104 cells were plate in a P96-well, fixed at day 0, day 1 and day 2 and the 
absorbance at 595nm upon the solubilization of the crystal violet dye was measured to determine the growth rate of cells. Data 
represent the mean±SEM of 4 independent measurements. Significance was determined by a two-way anova with ns p > 0.05. 
 
4.5. CXCL5 expressed by cancer cells regulate accumulation of neu-SiglecFhigh  
Once validated in vitro, WT and KOCXCL5 cells were injected into C57BL/6 mice to induce orthotopic 
lung cancer formation and Cxcl5 expression in tissues was assess by qRT-PCR, at two consecutive 
time points: at initial and at more advanced stage of tumorigenesis (Fig4.14a). Cxcl5 transcripts, as 
expected, were increased in WT tumor bearing lungs as compared to normal tissues, at both time 
points. In contrast, lungs of mice challenged with KOCXCL5 cells showed a minor increase in Cxcl5 
expression, even at later time point, confirming that the chemokine is produced primarily by cancer 
cells and not by other stromal cells conditioned by the tumor environmental factors (Fig.4.14b).  
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Figure 4.14 Challenging with WT or KOCXCL5 cells. A-B) Experimental scheme. Mice were intravenous injected with KP-OVA WT or 
KOCXCL5 cells and sacrificed at initial (9 days) or advanced (18 days) time points to analyse Cxcl5 expression in lungs. B) Cxcl5 relative 
abundance on Gapdh measured by qRT-PCR from normal or tumor bearing lung at initial and at advanced time points. Data represent 
the mean±SEM of 4-6 independent RNA extraction. Significance was determined by 2-way anova with *p≤0.05, **p≤0.01, 
****p≤0.0001. 
We next examined by flow cytometry how lack of cancer-derive CXCL5 impact on recruitment of the 
two subsets of neutrophils populating lung cancer.  We observed that frequencies of neu-SiglecFlow 
were similar between WT or KOCXCL5 tumor lungs as compared to nLung, at both initial and at more 
advanced time points. In addition, in line with data in Fig.4.3, neu-SiglecFhigh were highly 
represented in WT tumors and increased over time with tumor progression. Interestingly, tumors 
induced by KOCXCL5 cells did not show any increase in neu-SiglecFhigh at early time points and showed 
only a modest increased in more advanced tumors (Fig.4.15).   
 
Figure 4.15 Cxcl5-null tumor lungs fail to accumulate neu-SiglecF high. Mice were intravenous injected with KP-OVA WT or KOCXCL5 
cells and at initial and more advanced time point neu infiltrating normal and tumor bearing lungs were analysed by flow cytometry. 
Representative dot plot and quantification of relative abundance of SiglecF high/low neutrophils expressed as a fraction of CD45+ cells. 
Also, frequencies of SiglecF high/low neutrophils expressed on total CD11b+Ly6G+ were showed as % in the graph. Data represent the 
mean±SEM of 2 independent experiment, 3-4 mice each group.  
Furthermore, we performed IHC analysis by labelling paraffine embedded WT or KOCXCL5 lung tumor 
tissues with neu-specific Ly6G antibody (brown dots). In line with flow cytometry data, neu were 
detected within nodules of WT growing tumors. By contrast, IHC showed the lack of Ly6G labelling 
within tumor nodules of KOCXCL5 challenged mice, both at initial stages and in more advanced tumors 
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(Fig.4.16), confirming that lack of tumor-derived CXCL5 chemokine is sufficient to block the 
accumulation of neu in our model.  
 
Figure 4.16 IHC confirmed lack of neu in KOCXCL5 tumors. 20x representative sections and relative quantification of 𝛼Ly6G staining 
identifying neutrophils (brown dots) in WT (left) or KOCXCL5 (right) tumors at day 9 (upper sections) and at day 18 (lower sections). 
Frequencies, expressed as neutrophils within nodules identified by haematoxylin, represent the mean±SEM of 2-3 sections/mouse, 3 
mice each group. Significance was determined by a two-way anova with ****p≤0.0001. 
To explore whether the deletion of CXCL5 in lung cancer cells affects the recruitment of other 
immune subsets expressing CXCR2 receptor (such as macrophages 398 399 400), we used the gating 
strategy showed in Fig.4.2a to analyse by flow cytometry the immune landscape in KOCXCL5 tumor 
bearing lungs. Importantly, beside the significant reduction of neutrophils in KO tumors as 
compared to WT, we found no other statistically significant differences in immune composition 
between WT and KO tumors (Fig.4.17a). Moreover, to assess whether the lack of CXCL5 expression 
by tumor cells impacts on myelopoiesis in lymphoid organs or on circulating neutrophils, we 
analysed by flow cytometry frequencies of neutrophils in BM, spleen and blood of KOCXCL5 tumor 
bearing mice. We observed that frequencies of neutrophils increased in BM of KOCXCL5 bearing mice 
as compared to WT, however no statistically significant differences were observed in the spleen nor 
in blood of tumor bearing mice (Fig.4.17b-c). 
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Figure 4.17 Lack of tumor-derived CXCL5 selectively affect the neu-SiglecFhigh recruitment in tumor bearing lung. A-C) mice were 
challenged with WT or KOCXCL5 cells and 15 days after tumor induction mice were sacrificed to perform downstream analysis. A) 
Absolute numbers of different myeloid subsets were measured by counting beads by flow cytometry. Data represent the mean±SEM 
of 3-4 mice/group. Significance was determined by 2-way anova with ****p≤0.0001. B) frequencies of neu expressed as % of total 
cells were analysed in bone marrow and spleen by flow cytometry. Frequencies represent the mean±SEM of 3 mice/group. Significance 
was determined by one-way anova with **p≤0.01. C) frequencies of circulating neu were analysed at 2 time points. Data represent 
the mean±SEM of 5 mice/group. 
 
4.6. Re-expression of CXCL5 restore accumulation of neu-SiglecFhigh in lung tumors 
To ascertain that lack of neu accumulation in KOCXCL5 tumors is causally linked to the chemokine 
expression and does not depend on a clone specific effect, we restored CXCL5 expression in KP-OVA 
KOCXCL5 cells by lentiviral transduction. To this aim, we cloned the Cxcl5 coding sequence 
downstream of a CMV promoter in a lentiviral vector (lenti-vec). We produced lentiviral particles 
expressing CXCL5 (lenti-CXCL5) and we transduced the KP-OVA KOCXCL5 cells. In addition, the empty 
lenti-vec was used as negative control for lentiviral transduction. The transduced cells were selected 
under G418 resistance and the resultant KOCXCL5 (lenti-CXCL5) or (lenti-vec) validated in vitro for CXCL5 
expression (Fig.4.18).  
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Figure 4.18 Re-expression of CXCL5 in KO tumor cells by lentiviral transduction. KP-OVA KOCXCL5 cells were transduced with CXCL5-
expressing (lenti-CXCL5) or ctrl lentivirus (empty lenti-vec). Transduced cells were selected under G418 resistance and validated in 
vitro and in vivo. 
Thus, transduced KOCXCL5 cells were incubated at steady state with medium and the production of 
CXCL5 were assessed in the supernatant by ELISA. Furthermore, the results were compared with 
data of Figure 4.12b. We observed that the production of the chemokine was higher in KOCXCL5(lenti-
CXCL5) as compared to WT cell line. Conversely, KOCXCL5 and KOCXCL5 (lenti-vec) showed a null expression 
of CXCL5 (Fig4.19a). Moreover, we performed an intracellular staining by flow cytometry against 
HA-OVA to compare OVA expression in the transduced cells that was similar between the KP-OVA 
KOCXCL5(lenti-vec) and the re-expressing CXCL5 counterpart as showed in Figure 4.19b. Also, growth rate 
in vitro was analysed as in figure 4.13b and resulted to be equal between control and CXCL5 
expressing cells (Fig.4.19c).  
 
Figure 4.19 In vitro validation of CXCL5 re-expressing cells. A) The production of CXCL5 chemokine were measured by ELISA from the 
supernatant of cells after 5hrs of incubation. Data represent the mean±SEM of 2-5 independent measurements. Significance was 
determined by a two-way anova with ****p≤0.0001. B) Representative histogram of OVA expression measured by intracellular 
staining by flow cytometry in KP-OVA KOCXCL5(lenti-CXCL5) or KOCXCL5(lenti-vec) cells. The corresponding median of fluorescent intensity was 
plotted nearby each histogram. C) In-vitro growth curve of KOCXCL5(lenti-CXCL5) or (lenti-Vec) cells. 3x104 cells were plate in a P96-well and 
fixed at 3 different time points. Cells were incubated with crystal violet dye and upon its solubilization the absorbance at 595nm was 
measured. Data represents the mean±SEM of 4 independent measurements. Significance was determined by a two-way anova with 
ns p > 0.05.  
Thus, upon in vitro validation, we used the KOCXCL5 (lenti-CXCL5) and KOCXCL5 (lenti-vec) cells to induce 
orthotopic lung cancer formation and Cxcl5 expression in lung tissues upon challenge was measured 
by qRT-PCR. As shown in Figure 4.20a, in line with higher basal level observed in vitro, the expression 
of Cxcl5 was rescued in KOCXCL5(lenti-CXCL5) as compared to KOCXCL5 and was even higher than in WT 
tumors. As expected, lungs challenged with KOCXCL5(lenti-Vec) had similar expression to KOCXCL5 tumors.  
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Therefore, we analysed by flow cytometry the presence of the two subsets of neutrophils within 
lung tissues upon challenge with the CXCL5 re-expressing cells. Of note, accumulation of neu-
SiglecFhigh was restored in the TME of KOCXCL5(lenti-CXCL5) tumors, but not in control KOCXCL5(lenti-Vec). In 
addition, congruent with higher expression of CXCL5 showed in Figure 4.20a, in the setting of 
KOCXCL5(lenti-CXCL5) tumors, we noted a higher fraction of neu-SiglecFlow than in WT tumors, indicating 
that the chemokine alone is sufficient to induce neu influx. In conclusion, CXCL5 produced by KP 
tumor cells is the dominant factor inducing accumulation of neu in lung cancer and Cxcl5 deletion 
selectively and efficiently abrogates enrichment of neu-SiglecFhigh at the tumor site. 
 
Figure 4.20 Recruitment of neu-SiglecFhigh is restored in the TME of re-expressing KOCXCL5 cells. Mice were challenged with KP-OVA 
KOCXCL5 (lenti-CXCL5) or (lenti-Vec) and after 9 days lungs were analyzed. Data from previous experiments of WT and KOCXCL5 tumor bearing 
lung at initial stage were plotted together. A) relative abundance of Cxcl5 on Gapdh was measured by qRT-PCR from normal or tumor 
bearing lungs. Data represent the mean±SEM of 3-6 independent RNA extraction. Significance was determined by 2-way anova with 
**p≤0.01, ****p≤0.0001. B) Representative dot plot and relative abundance of SiglecF high/low neutrophils expressed as a fraction of 
CD45+ cells analysed by flow cytometry. Also, frequencies of SiglecF high/low neutrophils expressed on total CD11b+Ly6G+ were showed 
as % in the graph. Data represent the mean±SEM of one or two independent experiment, 3-4 mice each group.  
 
4.7. Absence of neu-SiglecFhigh lead to an expansion of tumor specific CD8 T cells 
Multiple reports documented T cell suppression by neutrophils using, in most cases, circulating or 
splenic neutrophils (refs in Tab.1). In a few studies, the impact of tissues infiltrating neu on T cell 
responses was investigated by Gr-1 or Ly6G mediated depletion, with the inherent limitations of 
these approaches 353 395. 
Presently, the functional significance of neu-SiglecFhigh populating KP tumors on endogenous anti-
tumoral T cells remains elusive. To address this question, we took advantage of the KOCXCL5 model 
to analyse T cell responses to KP-OVA tumors in a neu-SiglecFhigh competent or depleted tumor 
microenvironment. Considering their most relevant role in anti-cancer immune response and 
immunosurveillance 38 42 43, we focused the following analysis on early stages of tumorigenesis. 
Flow cytometry data did not show any differences in the frequencies of total CD8+ T cells within WT 
and KOCXCL5 lung tumors (Fig.4.21a). However, flow cytometry analysis using MHC-I-OVA pentamers 
to label OVA-specific CD8 T cells revealed that 7% of CD8 T cells infiltrating WT lung tumors are OVA 
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specific and that this fraction is 3-fold higher in KOCXCL5 tumor bearing lung, suggesting that absence 
of neu-SiglecFhigh permit a higher expansion of tumor specific CD8 T cells within tumor tissues 
(Fig.4.21b). 
 
Figure 4.21 tumor specific CD8 T cells expansion within KOCXCL5 tumors. A-B) Mice were challenged with WT or KOCXCL5 cells and 
frequencies of endogenous T cells were analysed by flow cytometry 9 days after induction in tumor bearing lung. A) Frequencies of 
endogenous CD8 T cells expressed as % of CD3+ cells were showed. Data represent the mean±SEM of 3 independent experiments with 
3-4 mice each group. Significance was determined by unpaired t-test with ns p>0.05. B) Frequencies of OVA specific CD8 T cells 
expressed as % of total CD8 T cells from healthy or tumor bearing lung were analyzed by MHCI-OVA pentamers by flow cytometry. 
Data represent the mean±SEM of 4 independent experiments with 4 mice/group. Significance was determined by one-way anova t 
test with **p≤0.01, ***p≤0.001, ****p≤0.0001. 
To corroborate this hypothesis, we labelled paraffine embedded WT or KOCXCL5 tumor bearing 
tissues with CD8 antibody to visualize the spatial distribution of CD8+ T cells (brown dots) within 
tissues. Despite FACS analysis did not show increased in overall frequencies (Fig.4.21a), IHC analysis 
showed that CD8+ T cells were enriched within nodules of KOCXCL5 tumors as compared to WT 
(Fig.4.22). 
 
Figure 4.22 CD8 T cells accumulate in nodules of KOCXCL5 tumors. Mice were challenged with WT or KOCXCL5 cells and 9 days after 
induction tumor bearing lungs were harvested to analyze CD8 T cell distribution by IHC. Thus, paraffine embedded WT or KOCXCL5 
tumor bearing lung tissues were labelled with CD8 antibody (brown dots). Quantification of CD8 T cells expressed as ratio of CD8 and 
tumor area measured by hematoxylin staining represent the mean±SEM of 3 independent experiments with 2-3 mice each group. 
Significance was determined by an unpaired t test with **p≤0.01. 
 
4.8. CD8 T cells in KOCXCL5 tumors are highly activated and cytotoxic  
To begin assessing the functionality of tumor infiltrating CD8 T cells in the two conditions, we started 
by testing expression of surface activation markers on CD8 T cells by flow cytometry. It has been 
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shown that CD8 T cells co-expressing PD-1, LAG3 and TIM3 include a group of highly activated and 
functional cells 95. As showed in Figure 4.23a, WT tumors were characterized by an expansion of up 
to 15% of triple positive CD8 T cells compared to nLung that was major in lungs of mice bearing 
KOCXCL5 tumors. Furthermore, we measured by flow cytometry the frequencies of CD62L- CD44+ CD8 
T cells, defined as effector memory T cells, in tumor bearing lungs. We observed an increase of this 
population in WT tumors as compared to nLung with the highest representation in KOCXCL5 tumors 
(Fig.4.23b). Lastly, we noticed an enrichment, that occurred only in KO tumors, of EOMES- T-bet+ 
CD8 T cells, which have been recently demonstrated to represent activated CD8 T cells that did not 
run the exhaustion program 93 (Fig.4.23c). Overall, these data showed that CD8 T cells are more 
active in a neu-SiglecFhigh depleted lung tumor microenvironment as compared to CD8 T cells in 
SiglecFhigh competent counterpart. To directly test the cytotoxic functions of CD8 T cells we next 
performed ex-vivo restimulation and intracellular staining to measure IFN- production. 
 
Figure 4.23 CD8 T cells activation in WT or KOCXCL5 tumors. A-C) Mice were inoculated with KP-OVA WT or KOCXCL5 cells and 9 days after 
challenge markers of activation/memory in CD8 T cells were analyzed by flow cytometry from normal or tumor bearing lungs. A) 
frequencies of triple positive (PD1+LAG3+TIM3+) CD8 T cells B) frequencies of effector memory (CD62l-CD44+) CD8 T cells and C) 
frequencies of effector EOMES-Tbet+ CD8 T cells, expressed as % of total CD8 T cells, were analyzed by flow cytometry. Data represent 
mean±SEM of 4-8 mice/group. Significance was determined by one-way anova with *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
We detected up to 5% of IFN- producing CD8 T cells in lung tissues bearing WT KP-OVA cells 
indicating activity of tumor infiltrating CD8 T cells. Remarkably, the fraction of IFN- producing CD8 
was twice as much in lungs of animal carrying KOCXCL5 tumors (Fig.4.24), indicating that CD8 T cells 
infiltrating lung tumors are more active and cytotoxic in absence of neu-SiglecFhigh. 
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Figure 4.24 CD8 T cells produce higher level of IFN-𝛾 in KOCXCL5 tumors. Representative dot plot and quantification of ex-vivo 
restimulation of endogenous CD8 T cells. Mice were injected with KP-OVA WT or KOCXCL5 and 9 days after challenge T cells from healthy 
or tumor bearing lung were re-stimulated ex-vivo 4hrs with SIINFEKL in presence of Golgi Stop and the IFN-𝛾 production measured by 
intracellular staining by flow cytometry. Data represent mean±SEM of 4 independent experiments with 4 mice each group. 
Significance was determined by one-way anova with **p≤0.01, ****p≤0.0001. 
To additionally demonstrate the causal link between the higher activation of CD8 T cells and the 
absence of neu-SiglecFhigh in lung tumor microenvironment, we performed the adoptive transfer 
(AT) of naïve OVA-specific CD8 T cells, isolated from OTI mice labelled with cell trace CFSE dye, into 
WT or KOCXCL5 tumor bearing mice. Two days after the AT we analyzed by flow cytometry the dilution 
of CFSE, corresponding to the proliferation of OTI CFSE+ T cells in vivo. As showed in Figure 4.25, the 
fraction of proliferated-OTI T cells was similar in WT and KOCXCL5 tumors.  
 
Figure 4.25 In vivo proliferation of transferred OVA specific CD8 T cells. Mice were challenged with WT or KOCXCL5 cells and 9 days after 
tumor induction, naïve OVA specific OTI CFSE+ T cells were adoptively transferred into tumor bearing mice and their proliferation was 
analyzed two days later by CFSE dilution by flow cytometry. Representative histogram of CFSE dilution and frequencies of proliferated 
OTI T cells for each cycle of proliferation expressed as % of total OTI were showed. Data represent the mean±SEM of 4 mice each 
group. Significance was determined by two-way anova. 
However, by ex-vivo restimulation of OT-I T cells performed as described before, we observed a 2-
fold higher frequency of IFN- producing OTI T cells in KOCXCL5 tumors as compared to WT, suggesting 
that exogenous tumor specific T cells transferred into a neu rich environment are induced to 
proliferate but their effector functions are suppressed by the presence of neu-SiglecFhigh (Fig.4.26).  
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Figure 4.26 Adoptively transferred OTI T cells produce higher level of IFN-𝛾 in KOCXCL5 tumors. Representative dot plot and 
quantification of ex-vivo restimulation of adoptively transferred OTI T cells. Mice were injected with KP-OVA WT or KOCXCL5 and 9 days 
after challenge naïve CD8 T cells isolated from OTI mice were adoptively transferred (AT) in tumor bearing mice. Two days after AT 
OTI T cells were re-stimulated ex-vivo 4hrs with SIINFEKL in presence of Golgi Stop and the IFN-𝛾 production measured by intracellular 
staining by flow cytometry. Data represent mean±SEM of 4 mice each group. Significance was determined by unpaired t-test with 
*p≤0.05. 
 
To furthermore underscore the importance of an appropriate system to assess neu-T cells crosstalk, 
we performed assays of CD8 T cell activation in the contest of a Ly6G-mediated neu depletion during 
challenge with KP OVA cells (Fig.4.8a).  
 
Figure 4.27 Mice were challenged with KP-OVA cells and starting from the 6th to 12th day treated every 3 days with 𝛼Ly6G or isotype 
to in vivo deplete neutrophils. Lungs were harvested at day 13th and frequencies of tumor specific CD8 T cells analysed by MHCI-OVA 
pentamers (left) and IFN- producing CD8 T cells upon ex-vivo restimulation with SIINFEKL and Golgi stop (right) were analysed by 
flow cytometry in normal or tumor bearing lungs. Frequencies expressed as % of total CD8 T cells represent the mean±SEM of 1 or 3 
experiments with 4-5 mice each group. Significance was determined by one-way anova with ns p>0.05, **p≤0.01, ***p≤0.001. 
Opposite to the rescue of T cell responses observed in KOCXCL5 tumors, neither the expansion of 
endogenous tumor specific CD8 T cells measured by MHC-I-OVA pentamers by flow cytometry (left), 
nor the increase of IFN- producing CD8 T cells upon ex-vivo restimulation (right) was observed in 
Ly6G-mediated neu depleted tumor bearing lung compare to KP-OVA tumors (Fig. 4.27), underling 
the relevance of KOCXCL5 model.  
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4.9. Increased number of effector memory CD8 T cells in mLN draining KO tumors 
Given that we found a small fraction of neu-SiglecFhigh in lymph nodes draining KP OVA lung tumors 
(Fig.4.4), we decided to analyze by flow cytometry the activation of CD8 T cell in mLN draining WT 
or KOCXCL5 tumor bearing lungs. We observed that activated triple positive PD1+LAG3+TIM3+ CD8 T 
cells are not represented in mLN (Fig.4.28a). On the other hand, consistent with higher activation 
of CD8 T cells observed in lungs bearing KO tumors, we observed a significative increase of effector 
memory CD8 T cells in mLN draining neu-SiglecFhigh deficient tumors as compared to mLN draining 
WT tumors in which instead the fraction of CD62l-CD44+ CD8 T cells was similar to nLung (Fig.4.28b). 
However, beside an increase if compared to mLN draining nLung, FACS analysis did not show any 
differences between fractions of effector EOMES-T-bet+ CD8 T in mLN draining WT and KOCXCL5 
tumors (Fig.4.28c), nor between frequencies of IFN- producing CD8 T cells upon ex-vivo 




Figure 4.28 Effector memory CD8 T cells increased in LNs draining KOCXCL5 tumors. A-D) Mice were challenged with KP-OVA WT or 
KOCXCL5 and T cell were analyzed by flow cytometry in LNs draining normal or tumor bearing lung (mLN). A) frequencies of triple 
positive (PD1+LAG3+TIM3+) CD8 T cells B) frequencies of effector memory (CD62l-CD44+) CD8 T cells and C) frequencies of effector 
EOMES-Tbet+ CD8 T cells, expressed as % of total CD8 T cells, were analyzed by flow cytometry. Frequencies represent the mean±SEM 
of 3-6 mice each group. Significance was determined by one-way anova with ns p>0.05, **p≤0.01. D) T cells from mLN of healthy or 
tumor bearing mice were re-stimulated ex-vivo 4hrs with SIINFEKL in presence of Golgi stop and the IFN-𝛾 production measured by 
intracellular staining by flow cytometry. Data represent the mean±SEM of 5 independent experiments with 3-4 mice each group. 
Significance was determined by one-way anova with ns p>0.05, *p≤0.05.  
 
4.10. CD4 T cells activation is not affected by neu-SiglecFhigh 
Beside the key role of CD8 T cells in cancer, also CD4 T cells can contribute to elimination phase of 
tumors 31 30. To assess whether the neu-SiglecFhigh impact on CD4 T cells functions, we analysed the 
expression of activation markers on CD4 T cells in WT or KOCXCL5 models by flow cytometry, both in 
lungs and draining lymph nodes (Fig. 4.29). FACS analysis showed that, WT and KOCXCL5 tumors were 
characterized by an increase of triple positive PD1+ LAG3+ TIM3+ CD4 T cells, even if in KO tumors it 
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was not statistically significant (Fig.4.29a-left). In line with data on CD8 T cells (Fig.4.28a), this 
population was not represented in draining lymph nodes (Fig.4.29b-left). In addition, we analysed 
by flow cytometry the frequencies of effector memory CD4 T cells in tumor bearing lungs. We noted 
that CD62l-CD44+ CD4 T cells expanded at the same rate in WT and KOCXCL5 tumor bearing lungs as 
compared to nLung (Fig.4.29a-right), and no differences were observed in draining lymph nodes 
(Fig.4.29b-right). Overall, these data suggest that neu-SiglecFhigh do not significantly impact on the 
activation of CD4 T cell compartment. 
 
Figure 4.29 CD4 T cell are not affected by neu-SiglecFhigh. A-B) Mice were challenged with KP-OVA WT or KOCXCL5 and 9 days after 
induction CD4 T cell were analyzed by flow cytometry in normal and tumor bearing lungs and corresponding draining lymph nodes. 
A) frequencies of triple positive (PD1+LAG3+TIM3+) CD4 T cells (left) and frequencies of effector memory (CD62l-CD44+) CD4 T cells 
(right) expressed as % of total CD4 T cells were analyzed by flow cytometry in normal or tumor bearing lungs. Frequencies represent 
mean±SEM of 1 or 2 experiments with 4 mice/group. Significance was determined by one-way anova with ns p>0.05, *p≤0.05, 
***p≤0.001. B) frequencies of triple positive (PD1+LAG3+TIM3+) CD4 T cells (left) and frequencies of effector memory (CD62l-CD44+) 
CD4 T cells (right) expressed as % of total CD4 T cells were analyzed by flow cytometry in lymph nodes draining normal or tumor 
bearing lungs. Frequencies represent the mean±SEM of 3-8 mice each group. Significance was determined by one-way anova with ns 
p>0.05. 
 
4.11. Neu-SiglecFhigh may reduce CD8 T cell activation by a contact dependent 
mechanism 
Inhibition of T cell functions by neu infiltrating tumors has been attributed to several pathways such 
as production of ROS, T cell anti-proliferative molecules, nutrient deprivation (Tab1). However, the 
mechanism underlying the T cell inhibitory potential of neu-SiglecFhigh is not known.  
We first explored whether neu-SiglecFhigh may impact on antigen presentation by cDC1s, a key 
subset to initiate T cell responses. We analysed by flow cytometry the maturation state of cDC1 in 
WT and KOCXCL5 models. Mature DCs upregulate the expression of molecules such as MHCII and 
CD86 acting as co-stimulatory molecules for T cells activation. FACS analysis showed that MHCII 
expression slightly increased on cDC1 from KOCXCL5 tumors as compared to WT, however the 
expression of CD86 molecule was similar between cDC1 from the two models (Fig.4.30). These data 
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suggest that at earlier time point of tumorigenesis when effects on CD8 T cells are already visible, 
cDC1 compartment is only marginally affected.  
 
Figure 4.30 Maturation of cDC1 was similar between WT and KOCXCL5 tumors. Mice were challenged with WT or KOCXCL5 cells and 9 
days after induction the expression of MHCII and CD86 were analyzed by flow cytometry on cDC1 from tumor bearing lungs. 
Representative histogram with corresponding median fluorescence intensity (MFI) were showed. Quantifications expressed as MFI 
fold on nLung represent the mean±SEM of 2 experiments with 5 mice each group. Significance was determined by unpaired t-test with 
*p≤0.05. 
As a second approach to understand mechanism of neu-SiglecFhigh mediated T cell suppression, we 
labelled paraffine embedded KP OVA tumors with both CD8 and Ly6G antibodies to study the 
relative spatial distribution of the two population within tumor nodules. We found nodules of 
different area at the initial stage of tumorigenesis tested. Interestingly, small nodules were heavily 
infiltrated by CD8 T cells and contained few neutrophils whereas nodules of intermediate size 
contained equal proportions of CD8 T cells and neutrophils. In contrast, large nodules were heavily 
enriched in neutrophils and depleted in CD8 T cells. In addition, we often observed CD8 T cell 
surrounded by neutrophils (Fig.4.31). Overall, these data suggest that neutrophils accumulating in 
lung tumor nodules, may directly impair CD8 T cell activation in a cell contact dependent manner or 






Figure 4.31 large nodules are mostly populated by neutrophils in KP OVA tumors. Mice were challenged with KP OVA cells and 9 days 
after induction tumor bearing lungs were harvested to analyze neutrophils and CD8 T cell distribution by IF. Thus, paraffine embedded 
KP OVA tumor tissues were labelled with Ly6G and CD8 antibodies. Nodules were classified based on area and inside each nodule 
neutrophils and CD8 T cells were quantified. Data represent the mean±SEM of 2 independent experiments with 2 mice each 
experiment. Significance was determined by two-way anova with *p≤0.05, **p≤0.01. 
 
4.12. Neu-SiglecFhigh contribute to tumor growth and limit PD-L1 blockade efficiency 
To evaluate how lack of neu-SiglecFhigh in the TME impact the tumor growth, we measured by H/E 
the tumor burden in paraffine embedded lungs after challenge with WT or KOCXCL5 cells, at two 
different time points. At initial time point, in line with higher activation of CD8 T cells described in 
previous chapters (4.7 and 4.8), tumor burden was reduced in KOCXCL5 tumors as compared to WT, 
however, this advantage was lost at more advanced stage of tumorigenesis. To corroborate this 
result, we performed IHC analysis by labelling the proliferating Ki67+ cells (brown dots) within 
nodules of paraffine embedded WT or KOCXCL5 tumor tissues. As expected, the proliferating cells 
were reduced in KO tumors when compared to WT at the initial time point. However, the difference 
was lost at later time point (Fig.4.32). Overall, these data suggest that tumor containment at initial 
time point of tumorigenesis in depleted neu-SiglecFhigh tumors, is bypassed at later stages.  
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Figure 4.32 Tumor growth was reduced in KOCXCL5 tumors. Mice were challenged with KP-OVA WT or KOCXCL5 cells and 9 or 18 days 
later lungs were paraffine embedded to perform downstream analysis by IHC. Representative sections of tumor burden (left) and 
representative 20x sections of proliferating Ki67+ cells (right-brown dots) were shown. Tumor burden was expresses as ratio of tumor 
area measured by H/E staining and total area of lobe. Proliferating cells were expressed as ratio of Ki67+ cells (brown dots) counted 
within nodules identified by eosin staining. Data represent the mean±SEM of 1 or 2 experiments with 4-5 mice each group. Significance 
was determined by one-way anova with ns p>0.05, *p≤0.05, **p≤0.01. 
Expression of inhibitory ligands on tumor cells and tumor infiltrating myeloid cells is a key obstacle 
to spontaneous T cell responses to tumor antigens 60 61. To assess whether neu-SiglecFhigh contribute 
to increase the burden of inhibitory signals in the TME, we measured by flow cytometry the 
expression of PD-L1 on neutrophils infiltrating KP OVA tumors. Of note, the expression of PD-L1 on 
tumor-derived neu-SiglecFlow was similar to neutrophils from nLung. By contrast, PD-L1 expression 
was significatively increased in SiglecFhigh counterpart (Fig.4.33a). Also, due to the lack of 
accumulation of neu-SiglecFhigh in KOCXCL5 model, the frequencies of PD-L1 expressing neu was 
consistently low as compared to WT tumors (Fig.4.33b). Therefore, we reasoned that blocking of 
neu-SiglecFhigh infiltration combined to check-point inhibitors could enhance rejection of tumors 
even at later time point.  
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Figure 4.33 High expression of PD-L1 on neu-SiglecFhigh. A) Mice were challenged with WT tumor cells and 15 days after induction PD-
L1 expression on neutrophils infiltrating normal or lung tumors were analyzed by flow cytometry. Representative histograms of PD-
L1 with corresponding median fluorescence intensity were shown. Relative quantification represents the mean±SEM of 2 experiments 
with 4 mice each group. Significance was determined by one-way anova with ns p>0.05, ****p≤0.0001. B) Mice were challenged with 
WT or KOCXCL5 tumor cells and after 15 days frequencies of neu expressing PD-L1 as % of CD45+ cells in normal or tumor bearing lungs 
were analyzed by flow cytometry.  
To assess this question, we administered blockade to PD-L1 in mice upon challenge with WT or 
KOCXCL5 cells as depicted in the scheme (Fig.4.34), therefore we analysed the tumor burden at 
advanced stage of tumor by H/E staining of paraffine embedded lung tumor tissues. 
 
Figure 4.34 Scheme of PD-L1 blockade. Mice were challenged with WT or KOCXCL5 and blockade to PD-L1 was administered every 3 
days from 3rd to 12th day. At 18th day mice were sacrificed and lung of treated tumor bearing mice were paraffine embedded to analyze 
the tumor growth by H/E analysis.  
Treatment with isotype used as control showed that, as expected, the tumor containment in 
depleted neu-SiglecFhigh tumors was bypassed at later stages and no differences in tumor growth 
were observed as compared to WT tumors. By opposite, PD-L1 blockade led to a strong reduction 
of tumor burden in mice carrying KOCXCL5 tumors, whereas had a marginal effect on the growth of 
WT tumors. In conclusion, these results show that neu-SiglecFhigh in lung cancer limit the efficacy of 
PD-L1 blockade (Fig.4.35).  
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Figure 4.35 PD-L1 blockade is more effective in KOCXCL5 tumors. Mice were challenged with WT or KOCXCL5 cells and blockade of PD-L1 
was administered as depicted in Figure 4.34. Representative sections and relative quantification of tumor burden from paraffine 
embedded tumor bearing lung treated with isotype or PD-L1 blockade were shown. Tumor burden was expressed as ratio of tumor 
area measured by H/E analysis and total area of lobe. Data represent the mean±SEM of 2 experiments with 3 mice each group. 






























5. Discussion  
Neutrophils represent an important component of the tumor microenvironment in different type 
of cancers, including lung cancer and are mostly associated to bad prognosis. Several studies 
demonstrated that neutrophils play an essential role in tumorigenesis and progression via induction 
of genetic instability 324 325, stimulation of angiogenesis 332 334 336, promotion of metastasis 279 353 296, 
enhancement of cancer cells proliferation 327 354 355 and modulation of immune system 368 274 362 287. 
Nevertheless, it has been proven that neutrophils mediate resistance against primary 
carcinogenesis in some cancer type and tumor stages through direct killing of cancer cells and 
activation of T cell-dependent anti-tumor immunity 57 383 387. Many factors are involved in their 
recruitment and polarization into phenotypically distinct pro- or anti-tumorigenic sub-populations. 
However, mechanisms behind these processes are still elusive and strongly dependent on the tumor 
type, the cellular microenvironment and immune modulating factors in the TME. Thus, assess the 
complexity of neutrophils in a specific microenvironment will provide the basis to develop new 
therapeutic approaches.  
Recently, scRNA-seq analysis allowed to identify different subsets of neutrophils in human NSCLC 
as well as in orthotopic lung adenocarcinoma model providing insight into lung tumor associated 
neutrophils heterogeneity 253 401. A critical subset of neutrophils expressing high levels of the sialic-
acid-binding protein SiglecF (neu-SiglecFhigh) was identified in KrasG12D/+; Trp53-/- (KP) mouse lung 
adenocarcinoma that correspond to a transcriptionally related human counterpart associated to 
negative outcomes 389. 
Neu-SiglecFhigh have been identified as bona-fide, mature and long-lived population associated to 
angiogenesis, extracellular matrix remodeling and T cell suppression that specifically accumulated 
in growing lung tumors 392 295. However, whether neutrophils are polarized within tumors or before 
reaching the tumor site, how neu-SiglecFhigh accumulation in lung tumors occur and their role on 
anti-cancer immune response are mostly unknown. In this manuscript, we used a transplantable KP 
cell line to assess the role of CXCL5 chemokine in neutrophils recruitment and explore their role in 
the lung tumor microenvironment.  
In line with above evidences, by a deeper characterization of the immune landscape of KP tumors 
by flow cytometry, we observed that neutrophils SiglecFhigh are absent in normal lung, whereas 
represented the 70% of total neutrophils in lung tumors. Neu-SiglecFhigh also accumulated in the 
presence of an ongoing response against tumor antigens giving us a model to study their role on 
anti-cancer immune response. By contrast, neu-SiglecFlow counterpart already populate healthy 
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lungs and were not associated to tumor promotion 253. Even if the role of lectin SiglecF on 
neutrophils has not been addressed, SiglecF was first associated with a suppressive role on 
eosinophils 391, overall suggesting that SiglecF could represent a marker to specifically identify pro-
tumorigenic tumor-associated neutrophils in lung cancer. We also observed, by flow cytometry 
analysis, a decrease in B cells and CD4 T cells in both immunogenic and not immunogenic tumor 
bearing lungs as compared to normal lung, an observation that deserves to be further investigated 
in the future considering the role of those subsets in adaptive anti-tumor immunity. 
In line with previous work 392, we were not able to identify by flow cytometry neutrophils expressing 
SiglecF neither in lymphoid organs (spleen, bone marrow and peripheric lymph nodes) nor into the 
circulation. By contrast, up to 20% of neu in lung draining lymph node were SiglecFhigh. Further 
studies to assess how neu-SiglecFhigh migrate into mLN and whether they could promote distant 
metastasis of lung cancer are required.   
In several reports, the role of neutrophils in shaping anti-tumoral immune response was assessed 
using ex-vivo assays based on circulating or splenic neutrophils, or by their antibodies-mediated in 
vivo depletion. Here, by flow cytometry and IHC analysis, we found that the Ly6G-mediated 
depletion of neutrophils was effective only on circulating neutrophils but was poorly efficient in 
depleting tumor infiltrating one. This result is in line with recent evidences by other group 395 and 
suggest cautions in interpretation of past results, especially concerning the role of tissue infiltrating 
neutrophil. This result also highlights the need to develop alternative ways to specifically target 
neutrophils in tissues.  
To explore the mechanism controlling accumulation of neu-SiglecFhigh in lung tumors, we profiled 
normal and tumor lung tissues using a gene array of chemokines and receptors. We observed that 
lung tumors are characterized by a huge over expression of the chemokine CXCL5, data confirmed 
also by qRT-PCR in both KP and its immunogenic counterpart. FACS analysis showed also that neu-
SiglecFhigh expressed higher levels of CXCL5-receptor, CXCR2, as compared to SiglecF low 
counterpart, axis which has been already linked to neutrophils recruitment in inflammation and 
cancer 309 304 306. In addition, from analysis of gene expression on CD45+ and CD45– populations 
isolated from normal and tumor bearing lungs, we pointed out that the chemokine is produced 
mainly by the not myeloid population in cancer which is composed by stromal and tumor cells. 
Taking into consideration that most of lung cancer arise from epithelial cells which have been 
demonstrated to be the main source of CXCL5 in tuberculosis infection 306, these data together 
suggest that tumor cells themselves may promote the recruitment of neutrophils expressing SiglecF 
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in lung tissues through CXCL5 production. To assess this hypothesis, we first analyzed the Cxcl5 
expression in several cell lines and unlike other tumor cells (including ovarian and melanoma cell 
lines) KP OVA cells did express high amount of the chemokine at steady state. Importantly, Lewis 
lung carcinoma cells (LLC), which is wild-type for Kras, did not express Cxcl5 at steady state, 
suggesting that, in line with previous reports 3 316 317, CXCL5 mediated neu-SiglecFhigh accumulation 
could be a peculiarity of lung tumors carrying Kras mutation.  
Thus, following data of gene expression, we generated by Crispr/Cas9 technology a null CXCL5 KP 
OVA cell line (KP OVA KOCXCL5). Those cells were firstly validated in vitro to exclude editing-related 
clone specific effects, thereafter we injected them to induce lung tumors in vivo. By qRT-PCR of 
tumor tissues, we observed that in KOCXCL5 tumors Cxcl5 transcript levels were lower as compared 
to WT tumors, even at later time point, confirming that the chemokine is produced mainly by cancer 
cells and not by other stromal cells conditioned by the tumor microenvironment. Impressively, flow 
cytometry and IHC analysis showed that KOCXCL5 tumor failed to accumulate neu-SiglecFhigh in lung 
tissues at initial stage of tumorigenesis and showed only a minor increased in more advanced 
tumors. This result demonstrated that lack of tumor-derived CXCL5 chemokine is sufficient to block 
accumulation of neutrophils expressing SiglecF in our model, without affect SiglecF low counterpart, 
normally present in lungs.  
Importantly, flow cytometry analysis also revealed that the lack of CXCL5 expression by cancer cells 
did not affect the recruitment of other immune cell subsets in lung tumors, including those 
expressing CXCR2 such as macrophages 398 399 400. In addition, flow cytometry data showed that lack 
of CXCL5 expression by tumor cells did not impact on frequencies of circulating and splenic 
neutrophils. Whereas it resulted in higher neutrophils content within bone marrow, likely reflecting 
less mobilization than in WT tumor. It is also possible that the over-expression of IL-6 in tumors 
lacking neu-SiglecFhigh (data not shown) could contribute to emergencies myelopoiesis 289 and 
increased frequencies of neutrophils observed in bone marrow of KOCXCL5 tumor bearing mice. 
However, further studies to assess the correlation between IL-6 overexpression and lack of tumor-
derived CXCL5 expression are needed.  
Importantly, tumors induced by CXCL5-restored KOCXCL5 cells showed an increase of Cxcl5 transcripts 
that was even higher as compared to WT tumors. We speculate that the strong promotor upstream 
from the Cxcl5 sequence in vector used for lentiviral production, may explain the higher expression 
of the chemokine in CXCL5-restored KOCXCL5 cells observed at steady state that led to inflated 
expression in tissues. Additionally, flow cytometry analysis showed that neu-SiglecFhigh influx was 
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restored in KOCXCL5 (lenti-CXCL5) tumors, demonstrating that their recruitment is causally linked to the 
chemokine expression.  
An open question is whether neutrophils are polarized within tumors or before reaching the tumor 
site. It has been shown that circulating lung tumor-derived molecules (such as sRAGE) are able to 
promote the activation of bone marrow-resident cells and consequent accumulation of neu-
SiglecFhigh in lungs 389, which suggest that polarization of neutrophils may occur before reaching the 
tumor site. On the other hand, evidences suggesting that TANs acquire a pro-tumorigenic 
phenotype within tissues along with tumor progression also exist. First, neutrophils with different 
states of polarization have been observed within the tumor itself 318 319. Moreover, it has been 
shown that tumor derived factors promote tissue accumulation of neutrophils with metabolic 
alteration and increased lifespan. The same authors also shown that acceleration of neutrophil 
turnover in lung tumors reduced frequencies of TANs expressing SiglecF which led to reduced tumor 
growth and augmented efficacy of radiotherapy 295.  
In the present work, congruent with the higher expression of CXCL5 at steady state and tissues, we 
observed a higher fraction of neu-SiglecFlow in KOCXCL5 (lenti-CXCL5) tumors as compared to WT, 
indicating that the chemokine alone is sufficient to induce neutrophils influx. In addition, we 
speculate that the higher fraction of neu-SiglecFlow in KOCXCL5 (lenti-CXCL5) tumors may reflect 
accelerated recruitment/turnover in tissues which is sufficient to counteract their pro-tumorigenic 
polarization in tissues. Nevertheless, future studies should address this open question by 
deciphering the exact mechanisms involved in neutrophils polarization, specifically in lung cancer.  
All together these data proved that CXCL5 produced by KP cells is the dominant factor inducing 
accumulation of neutrophils in lung cancer and Cxcl5 deletion selectively and efficiently abrogates 
enrichment of neu-SiglecFhigh at the tumor site, without affecting SiglecF low counterpart, providing 
a model to study their role on anti-cancer T cell response. In addition, ongoing bioinformatic analysis 
in our group will help to understand the relevance of the human homologous CXCL6 axis in human 
lung cancer.  
Flow cytometry analysis of WT and KOCXCL5 tumor bearing lung did not show any differences in 
frequencies of infiltrating CD8 T cells, however, lungs of animal carrying KO tumors were 
characterized by a higher expansion of endogenous tumor specific CD8 T cells as compared to WT. 
In addition, through a deeper characterization of CD8 T cells by flow cytometry, which include 
identification of activated cells co-expressing PD1/TIM3/LAG3 markers 95, effector memory CD62l-
CD44+ cells and effector EOMES-T-bet+ cells 93, we proved that CD8 T cells in KOCXCL5 tumors were 
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more activated and functional as compared to CD8 T cells in WT tumors, suggesting that neu-
SiglecFhigh may be responsible for suppression of CD8 T cells-mediated anti-cancer responses. 
Furthermore, by ex-vivo restimulation with OVA peptide of endogenous or transferred tumor 
specific T cells, we showed that the fraction of cytotoxic IFN-producing CD8 T cells importantly 
increased in KOCXCL5 tumors as compared to WT, corroborating the suppressive role of neutrophils 
expressing SiglecF on CD8 T cells. 
Despite the presence of neu-SiglecFhigh within mLN of tumor bearing mice, we did not observe any 
differences in activation of CD8 T cells nor in IFN production between mLNs draining WT and 
KOCXCL5 tumors, however, consistently with higher activation of CD8 T cells observed in KO tumor 
bearing lungs, we noted an increase of effector memory CD62l-CD44+ CD8+ T cells in mLNs draining 
tumors lacking neu-SiglecFhigh as compared to WT. 
In the setting of antibody-mediated neutrophils depletion, we observed any differences neither in 
frequencies of tumor specific CD8 T cells, nor in fraction of cytotoxic IFN-producing CD8 T cells in 
lung tumors, underlaying the importance of an appropriate system to assess neu-T cell crosstalk.  
Considering the emerging role of CD4 T cells in anti-cancer responses, we took advantages from our 
model to analyze the impact of neutrophils expressing SiglecF on CD4 T cell compartment by flow 
cytometry. Fractions of activated CD4 T cells co-expressing PD1/TIM3/LAG3 and effector memory 
CD62l-CD44+ CD4 T cells were similarly represented in lungs and draining lymph nodes of WT and 
KOCXCL5 tumor bearing mice, suggesting that neu-SiglecFhigh do not significantly affect CD4 T cell 
compartment.  
It has been showed that neutrophils are able to produce ROS 362 279, anti-proliferative molecules 287 
and other factors responsible for T cell suppression 367 368 303, however, tissue and subset specific T 
cell inhibitory mechanisms remain poorly defined.  
DCs, thanks to their ability to recognize tumor associated antigens and present processed-antigens 
to naïve T cells, inducing their activation, play an essential role in cancers 129. In particular, the most 
prominent role is carried out by cDC1s which, upon maturation, are able to cross-present 
extracellular antigens on MHCI molecules directly to CD8 T cells 131 43.  Looking for a mechanism of 
T cell suppression, firstly, we used KOCXCL5 model to assess the impact of neutrophils expressing 
SiglecF on cDC1c. Flow cytometry analysis showed a slight increase in maturation, characterized by 
enhanced MHCII, but not CD86 expression, of cDC1 deriving from KOCXCL5 tumors as compared to 
WT. Thus, at initial time point of tumorigenesis, when we performed the experiments on cDC1s and 
when the suppression of CD8 T cells was clearly visible, cDC1 compartment is only marginally 
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affected by the presence of neu-SiglecFhigh. Nevertheless, additional experiments to assess whether 
neutrophils expressing SiglecF impair cDC1 functions at more later time point are needed. 
As a second approach to understand mechanism of neu-SiglecFhigh mediated T cell suppression, we 
performed IF analysis of paraffine embedded KP OVA tumor bearing lungs to study the relative 
spatial distribution of neutrophils and CD8 T cells within tumor nodules. 
We pointed out that depending on the area of nodules, an inverse relation exists between the two 
populations. We observed that in small nodules, sparsely infiltrated by neutrophils, CD8 T cells 
represent a major fraction. By contrast, in large nodules neutrophils accumulated and were found 
often in touch with few CD8 T cells remaining, suggesting that neutrophils expressing SiglecF 
infiltrating tumor tissues may directly impair CD8 T cells activation by cell contact dependent 
manner or through their physically exclusion. However, further studies to identify the exact 
mechanisms of T cells suppression neu-SiglecFhigh mediated are required.  
We expected that the higher activation of CD8 T cells in a neu-SiglecFhigh depleted lung tumors may 
results in tumor containment as corroborated by IHC analysis of paraffine embedded tumor tissues 
which shown that both tumor burden and frequencies of proliferating cells within nodules were 
initially reduced in KOCXCL5 tumors as compared to WT. Nevertheless, previous works demonstrated 
that neutrophils-derived factors (leukotrienes, NE and growth factors) are able to promote tumor 
cells proliferation 353 354 355 358. In this setting, we cannot exclude direct effects of neutrophils 
expressing SiglecF on tumor cells and experiment of in vivo depletion of CD8 T cells are needed to 
establish a causal link between CD8 T cell suppression neu-SiglecFhigh mediated and tumor growth.  
Furthermore, IHC analysis showed that the tumor containment was bypassed at later time point, 
suggesting that tumors implement other suppressive mechanisms to avoid immune control.  
Tumor-intrinsic mechanisms of immune evasion include downregulation of MHCI expression and 
defects in antigen presentation 46 48, activation of oncogenic pathways 51, secretion of 
immunosuppressive molecules (such as IL10, TGF-, PGE2) and expression of inhibitory checkpoint 
molecules (such as PD-L1 and CTLA-4) 52 which combined result in a complex machinery for 
impairment of the anti-tumor response. In addition, growing evidence showed that different 
immune cell subsets including Tregs 75 198, TAMs 219 220 and TANs 370 371 372 express high level of 
immune checkpoint inhibitors which increase the burden of T cell inhibitory ligands.  
Of note, we observed that the expression of PD-L1 on tumor-derived neu-SiglecFlow was similar to 
neutrophils from nLung. By contrast, PD-L1 expression was significatively increased in SiglecFhigh 
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counterpart, corroborating the hypothesis that SiglecF could represent a marker to specifically 
identify pro-tumorigenic tumor-associated neutrophils in lung cancer.  
Furthermore, to assess whether the lower burden of T cell inhibitory ligands in tumors lacking neu-
SiglecFhigh may increase sensibility to checkpoint blockade, we administered antibodies to PD-L1 
upon challenge with WT and KOCXCL5 cells and we measured the tumor growth at advanced stage of 
tumorigenesis. Impressively, the treatment with immune checkpoint inhibitor was strongly effective 
in mice carrying KO tumors, while having a marginal effect in WT tumors, showing that neu-
SiglecFhigh in lung cancer limit the efficacy of PD-L1 blockade and their depletion combined with 
modern immunotherapy could represent a viable solution to counteract immune evasion.  
In conclusion, we demonstrated that CXCL5 produced by lung cancer cells carrying Kras mutation is 
a key regulator of accumulation of neutrophils expressing SiglecF in lung tissues. We provide a 
model that allow to study the crosstalk between T cells and specific subsets of neutrophils within 
lung tumors, overcoming issues related to studies which use not-tissue neutrophils with different 
localization and characteristics. We demonstrated that only neutrophils expressing SiglecF, and not 
SiglecFlow counterpart already present in normal lungs, contribute to T cell suppression and limit the 
efficacy of PD-L1 checkpoint blockade. Even if the exact molecular mechanisms of T cells 
suppression neutrophils-mediated required further investigation, we hypothesized that neutrophils 
may act in a contact-dependent manner or through exclusion of CD8 T cells from nodules of lung 
tumors. All together, these data suggest that targeting the CXCL5-axis could be a viable 
improvement to existing immunotherapy which could lead to achievement of a durable and wide 
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